2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T63c,Non-scarring alopecia, including androgenetic alopecia, alopecia areata, and telogen effluvium, is highly prevalent and often associated with significant psychosocial burden. Although treatments such as minoxidil and finasteride are available, variability in response and tolerability concerns have increased interest in alternative therapeutic approaches. Polyphenolic compounds have attracted attention due to their antioxidant, anti-inflammatory, and immunomodulatory properties. This systematic review and meta-analysis evaluated the efficacy of oral and topical polyphenolic interventions for hair regeneration in adults with non-scarring alopecia. A systematic search of PubMed/MEDLINE, Scopus, Web of Science, and Cochrane CENTRAL was conducted according to PRISMA 2020 guidelines (PROSPERO: CRD420251230149). Randomized, blinded controlled trials were included. Primary outcomes were objective trichoscopic measures, including hair density and total area hair count. Thirty-two randomized controlled trials involving 2,183 participants were analyzed. Compared with controls, polyphenolic interventions significantly improved hair density (SMD 0.90; 95% CI 0.51-1.30) and total area hair count (SMD 1.03; 95% CI 0.42-1.63), although substantial heterogeneity was observed. Direct comparisons with minoxidil did not show significant differences in overall hair count outcomes. Current evidence suggests that selected polyphenolic formulations may represent a potential adjunctive therapeutic approach in non-scarring alopecia, though further standardized and long-term trials are warranted.31:Ta1c, Background Low‐level laser therapy (LLLT) has emerged as a nonpharmacologic intervention for androgenetic alopecia (AGA), but evidence on its long‐term efficacy remains limited. Objective To evaluate the 12‐month effectiveness and safety of a home‐use helmet‐type LLLT device in individuals with AGA. Materials and Methods This prospective, open‐label study enrolled 68 patients (51 men, 17 women) with mild to severe AGA. Participants used a helmet‐type LLLT device emitting red light (646–675 nm) three times per week for 20 min over 48 weeks. Hair density and shaft thickness were assessed using phototrichogram at predefined intervals. Additional evaluations included blinded global photographic assessments and patient‐reported outcomes. Results Hair density increased significantly from a baseline mean of 99.2 ± 27.7 to 124.2 ± 33.1 hairs/cm 2 at 48 weeks (mean change +25.0 ± 28.1, p < 0.0001). Mean hair shaft thickness rose from 65.1 ± 11.8 to 74.9 ± 12.6 μm ( p < 0.0001), reflecting an approximate 15% improvement. Gains were consistent across sexes and AGA severity levels. By Week 48, 59% of participants were rated as improved based on global photographs, and over 85% expressed satisfaction with treatment. No adverse events related to the device were reported, and adherence was high throughout the study. Conclusion Twelve months of home‐use LLLT resulted in sustained improvements in hair density and thickness with excellent tolerability. These findings support its role as a safe, effective, and user‐friendly long‐term therapeutic option for patients with AGA. 32:T6ed,Society values a full head of hair. Therefore, androgenetic hair loss (AGA), though medically benign, can cause significant emotional distress. There is strong demand for alternative (nonconventional, over-the-counter) AGA treatments. It is important to have evidence on the efficacy of these treatments for AGA-especially in comparison with treatments that are approved by the United States Food and Drug Administration (FDA), such as oral finasteride and topical minoxidil. Following a systematic review, we conducted a network meta-analysis (NMA) to determine the relative efficacy of conventional monotherapies and selected alternative (nonconventional, over-the-counter) products for male AGA. We conducted a Bayesian NMA under a fixed effect model with uniform priors; the NMA estimated relative effects-as per mean difference (MD), along with the 95% credible interval (CI)-and surface under the cumulative ranking curve (SUCRA) values. We also assessed study-level evidence quality. Eligible studies were identified through systematic searches (without date restrictions) in PubMed and Scopus on April 30, 2025. The main outcome measure was change in total hair density at 24 weeks from baseline (in hairs/cm We found 24 eligible trials-where the relative efficacy of eight conventional monotherapies and seven alternative (nonconventional, over-the-counter) products was determined. The current NMA study confirms the efficacy of conventional monotherapies such as oral dutasteride, topical/oral minoxidil, and oral/topical finasteride for male AGA. We have provided guidance regarding the relative efficacy of some alternative (nonconventional, over-the-counter) agents (e.g., melatonin (topical) and rosemary oil (topical)) compared to conventional treatments.33:T866,ABSTRACTBackgroundSociety values a full head of hair. Therefore, androgenetic hair loss (AGA), though medically benign, can cause significant emotional distress. There is strong demand for alternative (nonconventional, over‐the‐counter) AGA treatments. It is important to have evidence on the efficacy of these treatments for AGA—especially in comparison with treatments that are approved by the United States Food and Drug Administration (FDA), such as oral finasteride and topical minoxidil.AimsFollowing a systematic review, we conducted a network meta‐analysis (NMA) to determine the relative efficacy of conventional monotherapies and selected alternative (nonconventional, over‐the‐counter) products for male AGA.MethodsWe conducted a Bayesian NMA under a fixed effect model with uniform priors; the NMA estimated relative effects—as per mean difference (MD), along with the 95% credible interval (CI)—and surface under the cumulative ranking curve (SUCRA) values. We also assessed study‐level evidence quality. Eligible studies were identified through systematic searches (without date restrictions) in PubMed and Scopus on April 30, 2025. The main outcome measure was change in total hair density at 24 weeks from baseline (in hairs/cm2).Results and ConclusionWe found 24 eligible trials—where the relative efficacy of eight conventional monotherapies and seven alternative (nonconventional, over‐the‐counter) products was determined. The current NMA study confirms the efficacy of conventional monotherapies such as oral dutasteride, topical/oral minoxidil, and oral/topical finasteride for male AGA. We have provided guidance regarding the relative efficacy of some alternative (nonconventional, over‐the‐counter) agents (e.g., melatonin (topical) and rosemary oil (topical)) compared to conventional treatments.34:T8a8,The results of small studies suggest that off-label use of low-dose oral minoxidil (LDOM) may be safe and effective for patients with hair loss, but larger trials and standardized guidelines are lacking. To create an expert consensus statement for LDOM prescribing for patients with hair loss. The current literature on the pharmacological properties, adverse effect profile, and use of LDOM for patients with hair loss was reviewed. Topics of interest were identified, and a modified Delphi consensus process was created. A total of 43 hair loss specialist dermatologists from 12 countries participated in a modified Delphi process. Consensus was reached if at least 70% agreed or strongly agreed on a 5-point Likert scale. Over 4 survey rounds, 180 items in the first round, 121 items in the second round, 16 items in the third round, and 11 items in the fourth round were considered and revised. A total of 76 items achieved consensus including diagnoses for which LDOM may provide direct or supportive benefit, indications for LDOM compared to topical minoxidil, dosing for adults (18 years and older) and adolescents (aged 12 to 17 years), contraindications, precautions, baseline evaluation, monitoring, adjunctive therapy, and specialty consultation. Pediatric use and dosing items for children younger than 12 years, and LDOM titration protocols fell short of consensus. This international expert consensus statement regarding the off-label prescribing of LDOM for patients with hair loss can help guide clinical practice until more data emerge. Hair loss experts with experience treating pediatric patients were underrepresented on this expert panel. Future research should investigate best practices for LDOM use in pediatric patients. Other critical topics for further investigation include the comparative efficacy of topical minoxidil vs oral minoxidil, the safety of oral minoxidil for patients with a history of allergic contact dermatitis to topical minoxidil, the long-term safety of LDOM, and the use of other off-label forms of minoxidil, such as compounded formulations of oral minoxidil and sublingual minoxidil. As additional evidence-based data emerge, these recommendations should be updated.35:Ta86,ImportanceThe results of small studies suggest that off-label use of low-dose oral minoxidil (LDOM) may be safe and effective for patients with hair loss, but larger trials and standardized guidelines are lacking.ObjectiveTo create an expert consensus statement for LDOM prescribing for patients with hair loss.Evidence ReviewThe current literature on the pharmacological properties, adverse effect profile, and use of LDOM for patients with hair loss was reviewed. Topics of interest were identified, and a modified Delphi consensus process was created. A total of 43 hair loss specialist dermatologists from 12 countries participated in a modified Delphi process. Consensus was reached if at least 70% agreed or strongly agreed on a 5-point Likert scale.FindingsOver 4 survey rounds, 180 items in the first round, 121 items in the second round, 16 items in the third round, and 11 items in the fourth round were considered and revised. A total of 76 items achieved consensus including diagnoses for which LDOM may provide direct or supportive benefit, indications for LDOM compared to topical minoxidil, dosing for adults (18 years and older) and adolescents (aged 12 to 17 years), contraindications, precautions, baseline evaluation, monitoring, adjunctive therapy, and specialty consultation. Pediatric use and dosing items for children younger than 12 years, and LDOM titration protocols fell short of consensus.Conclusions and RelevanceThis international expert consensus statement regarding the off-label prescribing of LDOM for patients with hair loss can help guide clinical practice until more data emerge. Hair loss experts with experience treating pediatric patients were underrepresented on this expert panel. Future research should investigate best practices for LDOM use in pediatric patients. Other critical topics for further investigation include the comparative efficacy of topical minoxidil vs oral minoxidil, the safety of oral minoxidil for patients with a history of allergic contact dermatitis to topical minoxidil, the long-term safety of LDOM, and the use of other off-label forms of minoxidil, such as compounded formulations of oral minoxidil and sublingual minoxidil. As additional evidence-based data emerge, these recommendations should be updated.36:T445,Among 90 enrolled participants, 68 completed the study; of these, the mean (SD) age was 36.6 (7.8) years. A total of 33 participants were enrolled in the oral minoxidil group and 35 in the topical treatment group. Both groups were homogenous in terms of demographic data and AGA severity. For the frontal area, the mean change from baseline to week 24 between groups was 3.1 hairs per cm2 (95% CI, -18.2 to 21.5; P = .27) for terminal hair density and 2.6 hairs per cm2 (95% CI, -10.3 to 15.8; P = .32) for total hair density. For the vertex area, the mean change from baseline to week 24 was 23.4 hairs per cm2 (95% CI, -0.3 to 43.0; P = .09) for terminal density and 5.5 hairs per cm2 (95% CI, -12.5 to 23.5; P = .32) for total hair density. According to the photographic analysis, oral minoxidil was superior to topical minoxidil on the vertex (24%; 95% CI, 0 to 48; P = .04) but not on the frontal scalp (12%; 95% CI, -12 to 36; P = .24). The most common adverse effects in the oral minoxidil group were hypertrichosis (22 of 45 [49%]) and headache (6 of 45 [14%]).37:T978,There has been increased interest in low-dose oral minoxidil for androgenetic alopecia (AGA) treatment. However, the efficacy of oral minoxidil for male AGA is yet to be evaluated in comparative therapeutic trials. To compare the efficacy, safety, and tolerability of daily oral minoxidil, 5 mg, vs twice-daily topical minoxidil, 5%, for 24 weeks in the treatment of male AGA. This double-blind, placebo-controlled randomized clinical trial was conducted at a single specialized clinic in Brazil. Eligible men with AGA aged 18 to 55 years classified using the Norwood-Hamilton scale as 3V, 4V, or 5V were included and randomized. Data were collected from January to December 2021, and data were analyzed from September 2022 to February 2023. Participants were randomized 1:1 into 2 groups: oral minoxidil, 5 mg, daily and topical placebo solution; or 1 mL of topical minoxidil, 5%, twice daily and oral placebo for 24 weeks. The primary outcome was change in terminal hair density on the frontal and vertex regions of the scalp. The secondary outcomes were change in total hair density and photographic evaluation. Among 90 enrolled participants, 68 completed the study; of these, the mean (SD) age was 36.6 (7.8) years. A total of 33 participants were enrolled in the oral minoxidil group and 35 in the topical treatment group. Both groups were homogenous in terms of demographic data and AGA severity. For the frontal area, the mean change from baseline to week 24 between groups was 3.1 hairs per cm2 (95% CI, -18.2 to 21.5; P = .27) for terminal hair density and 2.6 hairs per cm2 (95% CI, -10.3 to 15.8; P = .32) for total hair density. For the vertex area, the mean change from baseline to week 24 was 23.4 hairs per cm2 (95% CI, -0.3 to 43.0; P = .09) for terminal density and 5.5 hairs per cm2 (95% CI, -12.5 to 23.5; P = .32) for total hair density. According to the photographic analysis, oral minoxidil was superior to topical minoxidil on the vertex (24%; 95% CI, 0 to 48; P = .04) but not on the frontal scalp (12%; 95% CI, -12 to 36; P = .24). The most common adverse effects in the oral minoxidil group were hypertrichosis (22 of 45 [49%]) and headache (6 of 45 [14%]). In this study, oral minoxidil, 5 mg, once per day for 24 weeks did not demonstrate superiority over topical minoxidil, 5%, twice per day in men with AGA. Brazilian Registry of Clinical Trials Identifier: RBR-252w9r.38:Td8d,ImportanceThere has been increased interest in low-dose oral minoxidil for androgenetic alopecia (AGA) treatment. However, the efficacy of oral minoxidil for male AGA is yet to be evaluated in comparative therapeutic trials.ObjectiveTo compare the efficacy, safety, and tolerability of daily oral minoxidil, 5 mg, vs twice-daily topical minoxidil, 5%, for 24 weeks in the treatment of male AGA.Design, Setting, and ParticipantsThis double-blind, placebo-controlled randomized clinical trial was conducted at a single specialized clinic in Brazil. Eligible men with AGA aged 18 to 55 years classified using the Norwood-Hamilton scale as 3V, 4V, or 5V were included and randomized. Data were collected from January to December 2021, and data were analyzed from September 2022 to February 2023.InterventionsParticipants were randomized 1:1 into 2 groups: oral minoxidil, 5 mg, daily and topical placebo solution; or 1 mL of topical minoxidil, 5%, twice daily and oral placebo for 24 weeks.Main Outcomes and MeasuresThe primary outcome was change in terminal hair density on the frontal and vertex regions of the scalp. The secondary outcomes were change in total hair density and photographic evaluation.ResultsAmong 90 enrolled participants, 68 completed the study; of these, the mean (SD) age was 36.6 (7.8) years. A total of 33 participants were enrolled in the oral minoxidil group and 35 in the topical treatment group. Both groups were homogenous in terms of demographic data and AGA severity. For the frontal area, the mean change from baseline to week 24 between groups was 3.1 hairs per cm2 (95% CI, −18.2 to 21.5; P = .27) for terminal hair density and 2.6 hairs per cm2 (95% CI, −10.3 to 15.8; P = .32) for total hair density. For the vertex area, the mean change from baseline to week 24 was 23.4 hairs per cm2 (95% CI, −0.3 to 43.0; P = .09) for terminal density and 5.5 hairs per cm2 (95% CI, −12.5 to 23.5; P = .32) for total hair density. According to the photographic analysis, oral minoxidil was superior to topical minoxidil on the vertex (24%; 95% CI, 0 to 48; P = .04) but not on the frontal scalp (12%; 95% CI, −12 to 36; P = .24). The most common adverse effects in the oral minoxidil group were hypertrichosis (22 of 45 [49%]) and headache (6 of 45 [14%]).Conclusions and RelevanceIn this study, oral minoxidil, 5 mg, once per day for 24 weeks did not demonstrate superiority over topical minoxidil, 5%, twice per day in men with AGA.Trial RegistrationBrazilian Registry of Clinical Trials Identifier: RBR-252w9r25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Androgenetic Alopecia: condition Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on Androgenetic Alopecia (condition). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/condition/Androgenetic%20Alopecia\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Conditions\",\"item\":\"https://www.reachrx.ai/hub/tag/condition\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Androgenetic Alopecia\",\"item\":\"https://www.reachrx.ai/hub/tag/condition/Androgenetic%20Alopecia\"}]}}"}}]],["$","$L2f",null,{"title":"Androgenetic Alopecia: Research & Clinical Takeaways","description":"Discover peer-reviewed research on Androgenetic Alopecia with concise clinician summaries and next-step guidance.","papers":[{"doi":"10.1016/j.jid.2026.07.024","pmid":"42692190","title":"A causal effect of increased GLP1R expression on Male Pattern Hair Loss is suggested by Two-Sample Mendelian Randomization","journal_title":"Journal of Investigative Dermatology","journal_issn":"0022-202X","published_at":"2026-09-03T00:00:00.000Z","url":"https://doi.org/10.1016/j.jid.2026.07.024","source_score":243,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-09-07T06:30:45.916Z","updated_at":"2026-09-07T06:30:45.916Z","tags":[{"paper_doi":"10.1016/j.jid.2026.07.024","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1016/j.jid.2026.07.024","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1016/j.jid.2026.07.024","tag_type":"condition","value":"Androgenetic Alopecia","value_numeric":null},{"paper_doi":"10.1016/j.jid.2026.07.024","tag_type":"condition","value":"Male Pattern Hair Loss","value_numeric":null},{"paper_doi":"10.1016/j.jid.2026.07.024","tag_type":"impact_flag","value":"safety_signal","value_numeric":null},{"paper_doi":"10.1016/j.jid.2026.07.024","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1016/j.jid.2026.07.024","tag_type":"modality","value":"GLP-1 Receptor Agonist","value_numeric":null},{"paper_doi":"10.1016/j.jid.2026.07.024","tag_type":"sex","value":"male","value_numeric":null},{"paper_doi":"10.1016/j.jid.2026.07.024","tag_type":"study_design","value":"Mendelian Randomization Study","value_numeric":null},{"paper_doi":"10.1016/j.jid.2026.07.024","tag_type":"warning","value":"Level of evidence assigned as 3 (reflecting MR study design as observational-genetic evidence); MR studies do not provide the same certainty as RCTs.","value_numeric":null},{"paper_doi":"10.1016/j.jid.2026.07.024","tag_type":"warning","value":"No brand-name or generic drug tags applied as the paper studies GLP1R gene expression genetically, not a specific pharmaceutical agent — though clinical relevance extends to GLP-1 receptor agonist drug class.","value_numeric":null},{"paper_doi":"10.1016/j.jid.2026.07.024","tag_type":"warning","value":"The full text was not available; summary is based solely on title, DOI, journal, and publication metadata. Specific sample sizes, genetic instruments used, effect estimates, and sensitivity analyses could not be extracted.","value_numeric":null}],"summaries":{"what_studied":"A two-sample Mendelian randomization (MR) study evaluated whether genetically predicted increased GLP-1 receptor (GLP1R) expression has a causal effect on male pattern hair loss (androgenetic alopecia).","key_result":"The MR analysis suggested a causal relationship between increased GLP1R expression and male pattern hair loss, implying that GLP-1R signaling may promote androgenetic alopecia in men.","limitations":"Mendelian randomization relies on genetic instruments as proxies for GLP1R expression and cannot confirm biological mechanisms; findings may not generalize across ancestries if GWAS data were ancestry-specific; reverse causation and horizontal pleiotropy remain potential confounders despite MR design.","practice_takeaway":"Clinicians prescribing GLP-1 receptor agonists (e.g., semaglutide, liraglutide) should be aware of a possible causal link between GLP1R activity and male pattern hair loss, and may consider monitoring male patients for alopecia. This finding warrants prospective clinical validation before changing prescribing practice."}},{"doi":"10.1016/j.jaad.2026.07.057","pmid":"42606404","title":"Efficacy and safety of topical siRNA-based formulation targeting DKK-1 in androgenetic alopecia: A randomized, double-blind, vehicle-controlled trial","journal_title":"Journal of the American Academy of Dermatology","journal_issn":"0190-9622","published_at":"2026-08-17T00:00:00.000Z","url":"https://doi.org/10.1016/j.jaad.2026.07.057","source_score":8,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-28T06:25:19.968Z","updated_at":"2026-08-28T06:25:19.968Z","tags":[{"paper_doi":"10.1016/j.jaad.2026.07.057","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.07.057","tag_type":"condition","value":"Androgenetic Alopecia","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.07.057","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.07.057","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.07.057","tag_type":"modality","value":"RNA Interference (siRNA) Therapy","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.07.057","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.07.057","tag_type":"warning","value":"Only the paper metadata (title, DOI, journal, publication date) was provided — no abstract, methods, results, or conclusions were included. All structured fields requiring specific data (sample size, outcomes, limitations) are left null or set to placeholders. Clinicians should retrieve the full text before drawing any conclusions.","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.07.057","tag_type":"warning","value":"Publication date is August 17, 2026, which is recent relative to today (August 28, 2026); this paper may not yet be widely indexed or peer-reviewed commentary available.","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.07.057","tag_type":"warning","value":"The study design tag 'Randomized Controlled Trial' and level of evidence '2' are inferred from the trial description in the title, not confirmed from full-text methods.","value_numeric":null}],"summaries":{"what_studied":"A randomized, double-blind, vehicle-controlled trial evaluating the efficacy and safety of a topical siRNA-based formulation targeting DKK-1 (Dickkopf-1) in patients with androgenetic alopecia (AGA).","limitations":"The full text of this paper was not available for review; specific outcome data, sample size, duration, and statistical results cannot be confirmed or reported."}},{"doi":"10.1093/ced/llag333","pmid":"42546161","title":"Long-term effectiveness and safety of topical finasteride 0.25% monotherapy in male androgenetic alopecia: a 52-week real-world retrospective study","journal_title":"Clinical and Experimental Dermatology","journal_issn":"0307-6938","published_at":"2026-08-03T00:00:00.000Z","url":"https://doi.org/10.1093/ced/llag333","source_score":7,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-17T13:33:22.151Z","updated_at":"2026-08-17T13:33:22.151Z","tags":[{"paper_doi":"10.1093/ced/llag333","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1093/ced/llag333","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1093/ced/llag333","tag_type":"condition","value":"Androgenetic Alopecia","value_numeric":null},{"paper_doi":"10.1093/ced/llag333","tag_type":"generic","value":"finasteride","value_numeric":null},{"paper_doi":"10.1093/ced/llag333","tag_type":"impact_flag","value":"safety_signal","value_numeric":null},{"paper_doi":"10.1093/ced/llag333","tag_type":"level_of_evidence","value":"4","value_numeric":null},{"paper_doi":"10.1093/ced/llag333","tag_type":"modality","value":"5-Alpha Reductase Inhibitor","value_numeric":null},{"paper_doi":"10.1093/ced/llag333","tag_type":"sample_size","value":"n=123","value_numeric":123},{"paper_doi":"10.1093/ced/llag333","tag_type":"sex","value":"male","value_numeric":null},{"paper_doi":"10.1093/ced/llag333","tag_type":"study_design","value":"Retrospective Observational Study","value_numeric":null},{"paper_doi":"10.1093/ced/llag333","tag_type":"warning","value":"No control or placebo arm was included; all comparisons are intra-patient (before vs. after), so treatment effect size may be influenced by regression to the mean or natural disease fluctuation.","value_numeric":null},{"paper_doi":"10.1093/ced/llag333","tag_type":"warning","value":"Systemic absorption was not directly measured; the claim of minimal systemic exposure is inferred rather than pharmacokinetically confirmed in this study.","value_numeric":null},{"paper_doi":"10.1093/ced/llag333","tag_type":"warning","value":"The impact_flag 'safety_signal' is applied here as a positive signal (absence of systemic adverse events), not a harm signal — clinicians should interpret accordingly.","value_numeric":null}],"summaries":{"what_studied":"Evaluated topical finasteride 0.25% monotherapy in 123 adult men with androgenetic alopecia (AGA) over 52 weeks in a real-world retrospective setting, measuring trichoscopic outcomes (Total Hair Number, hair shaft thickness, terminal-to-vellus ratio) and safety at baseline vs. 52 weeks.","key_result":"At 52 weeks, Total Hair Number increased significantly at the vertex (+21.8 hairs/cm²; P < 0.001) and temporal regions (+29.4 hairs/cm²; P < 0.001), with improvements in hair shaft thickness and terminal-to-vellus ratio; 7.3% had mild local irritation, and no systemic sexual or mood adverse events were reported.","limitations":"Retrospective, single-center design without a control or comparator arm limits causal inference; no direct pharmacokinetic data on systemic absorption reported; relatively young mean age (32.4 years) may limit generalizability to older patients.","practice_takeaway":"For male AGA patients who are reluctant to use oral finasteride due to systemic side-effect concerns, topical finasteride 0.25% monotherapy offers meaningful hair density gains after one year with no reported systemic sexual or mood adverse events. The low rate of local irritation (7.3%) supports tolerability in routine practice."}},{"doi":"10.1007/s13555-026-01866-z","pmid":"42449043","title":"A 6-Month Prospective, Open-Label, Randomized Study Showing Increased Hair Growth Rate in Women Using Multi-Targeting Hair Growth Nutraceuticals","journal_title":"Dermatology and Therapy","journal_issn":"2193-8210","published_at":"2026-07-14T00:00:00.000Z","url":"https://doi.org/10.1007/s13555-026-01866-z","source_score":30,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-19T13:39:54.130Z","updated_at":"2026-07-19T13:39:54.130Z","tags":[{"paper_doi":"10.1007/s13555-026-01866-z","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01866-z","tag_type":"age_group","value":"older_adult","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01866-z","tag_type":"brand","value":"Nutrafol","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01866-z","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01866-z","tag_type":"condition","value":"Androgenetic Alopecia","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01866-z","tag_type":"condition","value":"Hair Thinning","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01866-z","tag_type":"condition","value":"Telogen Effluvium","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01866-z","tag_type":"generic","value":"ashwagandha","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01866-z","tag_type":"generic","value":"saw palmetto","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01866-z","tag_type":"generic","value":"tocotrienols","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01866-z","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01866-z","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01866-z","tag_type":"modality","value":"Nutraceutical Supplement","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01866-z","tag_type":"sample_size","value":"n=180","value_numeric":180},{"paper_doi":"10.1007/s13555-026-01866-z","tag_type":"sex","value":"female","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01866-z","tag_type":"study_design","value":"Prospective Open-Label Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01866-z","tag_type":"warning","value":"No placebo control group was included; all comparisons are within-subject vs. baseline, limiting causal conclusions.","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01866-z","tag_type":"warning","value":"Seven participants were concurrently using incretin-based therapies (e.g., GLP-1 agonists); post hoc subgroup results are pending a separate publication.","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01866-z","tag_type":"warning","value":"The postpartum formula arm enrolled non-postpartum women as surrogates; results may not directly apply to postpartum patients.","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01866-z","tag_type":"warning","value":"The study is described as 'randomized' in the title, but randomization appears to be by supplement group assignment based on life stage/diet, not blinded allocation — the study is effectively open-label observational within pre-assigned cohorts.","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01866-z","tag_type":"warning","value":"The study was fully funded by Nutraceutical Wellness, Inc. (Nutrafol manufacturer), and two authors are company employees — high conflict-of-interest risk.","value_numeric":null}],"summaries":{"what_studied":"Four oral botanical-based hair growth nutraceuticals (HGNs; Nutrafol Women Original, Advanced/vegan, Women's Balance for menopause, and Postpartum formulas) were evaluated over 6 months in 180 women aged 18–70 with self-reported and dermatologist-confirmed hair thinning, with assessments at days 0, 90, and 180 using Canfield HairMetrix® phototrichogram for linear hair growth rate (LHGR), hair counts, and anagen/telogen phases.","key_result":"All four HGN groups achieved statistically significant increases in LHGR by day 90, sustained through day 180 (p < 0.0001 for all groups), with relative gains of 18.6–36.7% above baseline (absolute gains ~0.04–0.06 mm/24 h). Terminal hair counts rose 6.0–7.9% and anagen hair counts rose 9.7–19.8% across groups at day 180; total scalp coverage increased 5.3–8.5%. 89–98% of participants subjectively agreed their hair was growing faster or longer.","limitations":"- Open-label, no placebo arm; placebo effect and natural temporal fluctuations in hair growth cannot be excluded.\n- The postpartum formula was tested in non-postpartum women to allow stable baseline measurement, limiting direct generalizability to the intended population.\n- Two of four authors are employees of the sponsor (Nutraceutical Wellness, Inc.), and the study was fully industry-funded, raising conflict-of-interest concern.","practice_takeaway":"These botanical-based oral supplements showed measurable increases in LHGR and hair counts in women with thinning hair, but the lack of a placebo control limits causal inference. Clinicians can consider them as adjuncts to established therapies, while awaiting placebo-controlled replication."}},{"doi":"10.1016/j.abd.2026.501400","pmid":"42398233","title":"Nanocarriers for topical minoxidil in androgenetic alopecia: systematic review of preclinical and clinical evidence","journal_title":"Anais Brasileiros de Dermatologia","journal_issn":"0365-0596","published_at":"2026-07-03T00:00:00.000Z","url":"https://doi.org/10.1016/j.abd.2026.501400","source_score":2,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-11T13:32:57.242Z","updated_at":"2026-07-11T13:32:57.242Z","tags":[{"paper_doi":"10.1016/j.abd.2026.501400","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/j.abd.2026.501400","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1016/j.abd.2026.501400","tag_type":"condition","value":"Androgenetic Alopecia","value_numeric":null},{"paper_doi":"10.1016/j.abd.2026.501400","tag_type":"generic","value":"minoxidil","value_numeric":null},{"paper_doi":"10.1016/j.abd.2026.501400","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1016/j.abd.2026.501400","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1016/j.abd.2026.501400","tag_type":"modality","value":"Nanocarrier Drug Delivery","value_numeric":null},{"paper_doi":"10.1016/j.abd.2026.501400","tag_type":"sample_size","value":"n=20","value_numeric":20},{"paper_doi":"10.1016/j.abd.2026.501400","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/j.abd.2026.501400","tag_type":"study_design","value":"Systematic Review","value_numeric":null},{"paper_doi":"10.1016/j.abd.2026.501400","tag_type":"warning","value":"Full text was inaccessible; summary is based solely on the abstract and results sections provided.","value_numeric":null},{"paper_doi":"10.1016/j.abd.2026.501400","tag_type":"warning","value":"Level of evidence set to 3 (systematic review of predominantly preclinical studies); the body of evidence is not equivalent to a systematic review of RCTs and should be interpreted cautiously.","value_numeric":null},{"paper_doi":"10.1016/j.abd.2026.501400","tag_type":"warning","value":"The sample_size tag reflects the number of included studies (n=20), not a patient-level N, as this is a systematic review — no pooled patient count was reported.","value_numeric":null},{"paper_doi":"10.1016/j.abd.2026.501400","tag_type":"warning","value":"The single human study assessed tolerability only in healthy volunteers, not efficacy in AGA patients — clinical applicability is very limited at this time.","value_numeric":null}],"summaries":{"what_studied":"Systematic review of preclinical and clinical evidence (2015–2024) on nanocarrier-based topical minoxidil (nanominoxidil) versus conventional minoxidil, placebo, or no treatment for androgenetic alopecia, across in vitro, ex vivo, in vivo, and human study designs.","key_result":"Across 20 eligible studies (19 preclinical + 1 human tolerability study), nanominoxidil consistently increased follicular deposition and cutaneous retention ≈2- to >7-fold versus conventional solutions; hair growth surrogates and angiogenic/stem-cell markers were improved. Local tolerability was generally acceptable and systemic exposure was negligible.","limitations":"- Evidence is almost entirely preclinical; the single human study assessed tolerability only in healthy volunteers, not therapeutic efficacy in AGA patients.\n- High heterogeneity in models, comparators, doses, follow-up, and outcomes prevented meta-analysis.\n- Frequent lack of randomization, blinding, and standardized safety reporting limits internal validity and generalizability.","practice_takeaway":"Nanominoxidil formulations show promising follicular targeting in the lab but have no randomized clinical trial data in AGA patients — do not substitute for standard topical minoxidil in routine practice yet. Clinicians should watch for upcoming RCTs before adopting these formulations."}},{"doi":"10.2147/ccid.s590767","pmid":"42502353","title":"A Bidirectional Mendelian Randomization Study of Androgenetic Alopecia and Obesity","journal_title":"Clinical, Cosmetic and Investigational Dermatology","journal_issn":"1178-7015","published_at":"2026-07-01T00:00:00.000Z","url":"https://doi.org/10.2147/ccid.s590767","source_score":1,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-29T13:31:18.584Z","updated_at":"2026-07-29T13:31:18.584Z","tags":[{"paper_doi":"10.2147/ccid.s590767","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.2147/ccid.s590767","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.2147/ccid.s590767","tag_type":"condition","value":"Androgenetic Alopecia","value_numeric":null},{"paper_doi":"10.2147/ccid.s590767","tag_type":"condition","value":"Obesity","value_numeric":null},{"paper_doi":"10.2147/ccid.s590767","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.2147/ccid.s590767","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.2147/ccid.s590767","tag_type":"sample_size","value":"n=706028","value_numeric":706028},{"paper_doi":"10.2147/ccid.s590767","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.2147/ccid.s590767","tag_type":"study_design","value":"Mendelian Randomization Study","value_numeric":null},{"paper_doi":"10.2147/ccid.s590767","tag_type":"warning","value":"Level of evidence assigned as 3 (genetic epidemiology/MR study); MR does not map cleanly onto traditional RCT-based hierarchies.","value_numeric":null},{"paper_doi":"10.2147/ccid.s590767","tag_type":"warning","value":"Sample size reported is the combined total of all GWAS participants across both datasets (AGA: 207,036; obesity: 500,192); individual study Ns differ by exposure/outcome direction. The combined figure is an approximation for tagging purposes.","value_numeric":null},{"paper_doi":"10.2147/ccid.s590767","tag_type":"warning","value":"The 'impact_flag' confirms_prior is assigned because the MR null finding aligns with some prior population-based studies that also failed to replicate the obesity-AGA association, though it contradicts other observational reports.","value_numeric":null}],"summaries":{"what_studied":"Bidirectional two-sample Mendelian randomization (MR) was used to test whether obesity causally affects androgenetic alopecia (AGA) risk, and vice versa, using large-scale European-ancestry GWAS data (66,172 AGA cases; 31,499 obese cases) with 53 SNPs as obesity instruments and 212 SNPs as AGA instruments.","key_result":"No causal effect was found in either direction: obesity→AGA (IVW OR=1.01, 95% CI 0.98–1.04, P=0.58) and AGA→obesity (IVW OR=1.00, 95% CI 0.99–1.01, P=0.83). All five MR methods and sensitivity analyses (MR-Egger intercept P=0.35 and P=0.067) were consistent with no directional pleiotropy.","limitations":"- GWAS data were exclusively European-ancestry, limiting generalizability to other ethnic groups.\n- Residual cryptic pleiotropy cannot be fully excluded despite random-effects IVW and sensitivity analyses.\n- Multivariable MR to account for shared metabolic confounders was not performed.","practice_takeaway":"Clinicians can reassure patients that obesity and AGA are not causally linked; prior observational associations likely reflect shared confounders rather than a direct biological relationship. Treating obesity should not be framed as a strategy to prevent or reverse AGA."}},{"doi":"10.1080/09546634.2026.2654112","pmid":"42057730","title":"Efficacy of polyphenolic compounds for hair regeneration: a systematic review and meta-analysis of randomized controlled trials","journal_title":"Journal of Dermatological Treatment","journal_issn":"0954-6634","published_at":"2026-04-30T00:00:00.000Z","url":"https://doi.org/10.1080/09546634.2026.2654112","source_score":6,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2026-05-08","doi":"10.1080/09546634.2026.2654112","days":"7","issn":"0954-6634","rank":"6","field":"Clinical Medicine","score":"6","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1080/09546634.2026.2654112","title":"Efficacy of polyphenolic compounds for hair regeneration: a systematic review and meta-analysis of randomized controlled trials.","journal":"The Journal of dermatological treatment","methods":"","results":"Thirty-two randomized controlled trials involving 2,183 participants were analyzed. Compared with controls, polyphenolic interventions significantly improved hair density (SMD 0.90; 95% CI 0.51-1.30) and total area hair count (SMD 1.03; 95% CI 0.42-1.63), although substantial heterogeneity was observed. Direct comparisons with minoxidil did not show significant differences in overall hair count outcomes.","abstract":"$30","keywords":["Polyphenols","androgenetic alopecia","botanical extracts","hair density","meta-analysis","randomized controlled trials"],"pubmed_id":"42057730","conclusions":"","publication_date":"2026-04-30T00:00:00"},"crossref":{"DOI":"10.1080/09546634.2026.2654112","URL":"https://doi.org/10.1080/09546634.2026.2654112","ISSN":["0954-6634","1471-1753"],"link":[{"URL":"https://www.tandfonline.com/doi/pdf/10.1080/09546634.2026.2654112","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":"1","score":1,"title":["Efficacy of polyphenolic compounds for hair regeneration: a systematic review and meta-analysis of randomized controlled trials"],"author":[{"given":"Chaimae","family":"El Ammari","sequence":"first","affiliation":[{"name":"UCAM HiTech Sport & Health Innovation Hub, Universidad Católica de Murcia"},{"name":"Group of Metabolism and Gene Regulation, UCAM HiTech Sport & Health Innovation Hub, Universidad Católica de Murcia"}]},{"given":"Ana María","family":"García-Muñoz","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy and Nutrition, UCAM Universidad Católica San Antonio de Murcia"}]},{"given":"Rubén","family":"Zapata-Pérez","sequence":"additional","affiliation":[{"name":"UCAM HiTech Sport & Health Innovation Hub, Universidad Católica de Murcia"},{"name":"Group of Metabolism and Gene Regulation, UCAM HiTech Sport & Health Innovation Hub, Universidad Católica de Murcia"}]},{"given":"Rubén","family":"Rabadán-Ros","sequence":"additional","affiliation":[{"name":"UCAM HiTech Sport & Health Innovation Hub, Universidad Católica de Murcia"},{"name":"Group of Metabolism and Gene Regulation, UCAM HiTech Sport & Health Innovation Hub, Universidad Católica de Murcia"}]},{"given":"Carmen","family":"Lucas-Abellán","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy and Nutrition, UCAM Universidad Católica San Antonio de Murcia"}]},{"given":"Rebeca","family":"González-Louzao","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy and Nutrition, UCAM Universidad Católica San Antonio de Murcia"}]},{"given":"Desirée","family":"Victoria-Montesinos","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy and Nutrition, UCAM Universidad Católica San Antonio de Murcia"}]}],"issued":{"date-parts":[[2026,4,30]]},"member":"301","prefix":"10.1080","source":"Crossref","volume":"37","created":{"date-time":"2026-04-30T08:17:27Z","timestamp":1777537047000,"date-parts":[[2026,4,30]]},"indexed":{"date-time":"2026-05-04T03:44:07Z","timestamp":1777866247049,"date-parts":[[2026,5,4]]},"license":[{"URL":"http://creativecommons.org/licenses/by-nc/4.0/","start":{"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000,"date-parts":[[2026,4,30]]},"delay-in-days":0,"content-version":"vor"}],"subject":[],"abstract":null,"language":"en","relation":{},"resource":{"primary":{"URL":"https://www.tandfonline.com/doi/full/10.1080/09546634.2026.2654112"}},"subtitle":[],"assertion":[{"name":"peerreview_statement","label":"Peer Review Statement","order":1,"value":"The publishing and review policy for this title is described in its Aims & Scope."},{"URL":"http://www.tandfonline.com/action/journalInformation?show=aimsScope&journalCode=ijdt20","name":"aims_and_scope_url","label":"Aim & Scope","order":2,"value":"http://www.tandfonline.com/action/journalInformation?show=aimsScope&journalCode=ijdt20"},{"name":"received","group":{"name":"publication_history","label":"Publication History"},"label":"Received","order":0,"value":"2026-02-16"},{"name":"accepted","group":{"name":"publication_history","label":"Publication History"},"label":"Accepted","order":2,"value":"2026-03-28"},{"name":"published","group":{"name":"publication_history","label":"Publication History"},"label":"Published","order":3,"value":"2026-04-30"}],"deposited":{"date-time":"2026-04-30T08:17:33Z","timestamp":1777537053000,"date-parts":[[2026,4,30]]},"issn-type":[{"type":"print","value":"0954-6634"},{"type":"electronic","value":"1471-1753"}],"published":{"date-parts":[[2026,4,30]]},"publisher":"Informa UK Limited","reference":[{"DOI":"10.1016/j.reth.2022.10.005","key":"e_1_3_3_2_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1002/lsm.23017","key":"e_1_3_3_3_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.2147/CCID.S284435","key":"e_1_3_3_4_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_3_3_5_1","year":"2017","issue":"6","author":"Juárez-Rendón KJ","volume":"115","first-page":"e404","unstructured":"Juárez-Rendón KJ, Rivera Sánchez G, Reyes-López MÁ, et al. Alopecia Areata. Current situation and perspectives. Arch Argent Pediatr. 2017;115(6):e404–e411. 11.","article-title":"Alopecia Areata. Current situation and perspectives","journal-title":"Arch Argent Pediatr","doi-asserted-by":null},{"DOI":"10.3390/ph18020138","key":"e_1_3_3_6_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3390/molecules27227832","key":"e_1_3_3_7_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1136/bmj.n71","key":"e_1_3_3_8_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1002/9781119536604","key":"e_1_3_3_9_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1002/9781119536604.ch8","key":"e_1_3_3_10_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_3_3_11_1","year":"2018","issue":"5","author":"Ablon G","volume":"17","first-page":"558","unstructured":"Ablon G, Kogan S. A six-month, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of a nutraceutical supplement for promoting hair growth in women with self-perceived thinning hair. J Drugs Dermatol. 2018;17(5):558–565.","article-title":"A six-month, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of a nutraceutical supplement for promoting hair growth in women with self-perceived thinning hair","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":"10.3390/life15030500","key":"e_1_3_3_12_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/jocd.16778","key":"e_1_3_3_13_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.56609/jac.v41i2.276","key":"e_1_3_3_14_1","year":"2023","issue":"2","author":"Biasio FD","volume":"41","first-page":"28","unstructured":"Biasio FD, Ielpo A, Santarsiere L, et al. A randomized double-blind placebo-controlled clinical trial to evaluate the effect of an Annurca apple supplement formula in androgenic alopecia. J Appl Cosmetol. 2023;41(2):28–46.","article-title":"A randomized double-blind placebo-controlled clinical trial to evaluate the effect of an Annurca apple supplement formula in androgenic alopecia","journal-title":"J Appl Cosmetol","doi-asserted-by":"crossref"},{"DOI":"10.1002/hsr2.1045","key":"e_1_3_3_15_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/ics.12783","key":"e_1_3_3_16_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.2174/0118743722294678240502110214","key":"e_1_3_3_17_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1155/2014/549721","key":"e_1_3_3_18_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1248/bpb.b15-00387","key":"e_1_3_3_19_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.22159/ajpcr.2021.v14i8.41859","key":"e_1_3_3_20_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3109/09546639609086878","key":"e_1_3_3_21_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/srt.13448","key":"e_1_3_3_22_1","year":"2023","issue":"9","author":"Ham S","volume":"29","first-page":"e13448","unstructured":"Ham S, Lee YI, Kim IA, et al. Efficacy and safety of persimmon leaf formulated with green tea and sophora fruit extracts (BLH308) on hair growth: a randomized, double-blind, placebo-controlled clinical trial. Skin Res Technol. 2023;29(9):e13448.","article-title":"Efficacy and safety of persimmon leaf formulated with green tea and sophora fruit extracts (BLH308) on hair growth: a randomized, double-blind, placebo-controlled clinical trial","journal-title":"Skin Res Technol","doi-asserted-by":"crossref"},{"DOI":"10.1111/dth.13734","key":"e_1_3_3_23_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3390/antiox14040477","key":"e_1_3_3_24_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3390/nu17050767","key":"e_1_3_3_25_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.fshw.2023.02.043","key":"e_1_3_3_26_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_3_3_27_1","year":"2013","issue":"1","author":"Loing E","volume":"64","first-page":"45","unstructured":"Loing E, Lachance R, Ollier V, et al. A new strategy to modulate alopecia using a combination of two specific and unique ingredients. J Cosmet Sci. 2013;64(1):45–58.","article-title":"A new strategy to modulate alopecia using a combination of two specific and unique ingredients","journal-title":"J Cosmet Sci","doi-asserted-by":null},{"DOI":null,"key":"e_1_3_3_28_1","year":"2020","issue":"10","author":"Lueangarun S","volume":"13","first-page":"32","unstructured":"Lueangarun S, Panchaprateep R. An herbal extract combination (Biochanin A, Acetyl tetrapeptide-3, and ginseng extracts) versus 3% minoxidil solution for the treatment of androgenetic alopecia: a 24-week, prospective, randomized, triple-blind, controlled trial. J Clin Aesthetic Dermatol. 2020;13(10):32–37.","article-title":"An herbal extract combination (Biochanin A, Acetyl tetrapeptide-3, and ginseng extracts) versus 3% minoxidil solution for the treatment of androgenetic alopecia: a 24-week, prospective, randomized, triple-blind, controlled trial","journal-title":"J Clin Aesthetic Dermatol","doi-asserted-by":null},{"DOI":"10.1111/jocd.14931","key":"e_1_3_3_29_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3390/biom13040699","key":"e_1_3_3_30_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_3_3_31_1","year":"2015","issue":"1","author":"Panahi Y","volume":"13","first-page":"15","unstructured":"Panahi Y, Taghizadeh M, Marzony ET, et al. Rosemary oil vs minoxidil 2% for the treatment of androgenetic alopecia: a randomized comparative trial. Skinmed. 2015;13(1):15–21.","article-title":"Rosemary oil vs minoxidil 2% for the treatment of androgenetic alopecia: a randomized comparative trial","journal-title":"Skinmed","doi-asserted-by":null},{"DOI":"10.15570/actaapa.2018.13","key":"e_1_3_3_32_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1159/000540081","key":"e_1_3_3_33_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3109/09546634.2011.568470","key":"e_1_3_3_34_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1177/27683605251363174","key":"e_1_3_3_35_1","year":"2025","issue":"10","author":"Revathi R","volume":"31","first-page":"921","unstructured":"Revathi R, Suhag D. Amaranthus extract promotes healthy follicles and anagen hair density-A randomized placebo-controlled, double-blinded study. J Integr Complement Med. 2025;31(10):921–931.","article-title":"Amaranthus extract promotes healthy follicles and anagen hair density-A randomized placebo-controlled, double-blinded study","journal-title":"J Integr Complement Med","doi-asserted-by":"crossref"},{"DOI":"10.1002/ptr.800","key":"e_1_3_3_36_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/ced.12753","key":"e_1_3_3_37_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1177/2515690X241291141","key":"e_1_3_3_38_1","year":"2024","issue":null,"author":"Tanuphol N","volume":"29","first-page":null,"unstructured":"Tanuphol N, Waranuch N, Wisuitiprot V, et al. Effectiveness and safety of hair growth formulation containing Tectona grandis L.f (teak) leaf extract: a randomized, double-blind, placebo-controlled study on males with androgenic alopecia. J Evid-Based Integr Med. 2024;29:2515690X241291141.","article-title":"Effectiveness and safety of hair growth formulation containing Tectona grandis L.f (teak) leaf extract: a randomized, double-blind, placebo-controlled study on males with androgenic alopecia","journal-title":"J Evid-Based Integr Med","doi-asserted-by":"crossref"},{"DOI":"10.1089/jmf.2017.0016","key":"e_1_3_3_39_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3390/cosmetics11050146","key":"e_1_3_3_40_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/jocd.14158","key":"e_1_3_3_41_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.4103/tjd.tjd_41_22","key":"e_1_3_3_42_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1080/09546634.2021.1945527","key":"e_1_3_3_43_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1365-2133.2004.05785.x","key":"e_1_3_3_44_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1017/jns.2016.41","key":"e_1_3_3_45_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1046/j.0007-0963.2001.04558.x","key":"e_1_3_3_46_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.2147/DDDT.S327378","key":"e_1_3_3_47_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"}],"short-title":[],"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"update-policy":"https://doi.org/10.1080/tandf_crossmark_01","alternative-id":["10.1080/09546634.2026.2654112"],"article-number":"2654112","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"original-title":[],"container-title":["Journal of Dermatological Treatment"],"published-print":{"date-parts":[[2026,12,31]]},"reference-count":46,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2026,4,30]]},"references-count":46,"short-container-title":["Journal of Dermatological Treatment"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1080/09546634.2026.2654112","is_oa":true,"title":"Efficacy of polyphenolic compounds for hair regeneration: a systematic review and meta-analysis of randomized controlled trials","updated":"2026-05-06T13:23:02+00:00","published_date":"2026-04-30","best_oa_location":{"url":"https://doi.org/10.1080/09546634.2026.2654112","pmh_id":null,"url_for_pdf":null,"url_for_landing_page":"https://doi.org/10.1080/09546634.2026.2654112"}}},"created_at":"2026-05-14T13:22:51.771Z","updated_at":"2026-05-14T15:13:26.918Z","tags":[{"paper_doi":"10.1080/09546634.2026.2654112","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1080/09546634.2026.2654112","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1080/09546634.2026.2654112","tag_type":"condition","value":"Alopecia Areata","value_numeric":null},{"paper_doi":"10.1080/09546634.2026.2654112","tag_type":"condition","value":"Androgenetic Alopecia","value_numeric":null},{"paper_doi":"10.1080/09546634.2026.2654112","tag_type":"condition","value":"Telogen Effluvium","value_numeric":null},{"paper_doi":"10.1080/09546634.2026.2654112","tag_type":"generic","value":"finasteride","value_numeric":null},{"paper_doi":"10.1080/09546634.2026.2654112","tag_type":"generic","value":"minoxidil","value_numeric":null},{"paper_doi":"10.1080/09546634.2026.2654112","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1080/09546634.2026.2654112","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1080/09546634.2026.2654112","tag_type":"level_of_evidence","value":"1","value_numeric":null},{"paper_doi":"10.1080/09546634.2026.2654112","tag_type":"modality","value":"Polyphenolic Compound","value_numeric":null},{"paper_doi":"10.1080/09546634.2026.2654112","tag_type":"sample_size","value":"n=2183","value_numeric":2183},{"paper_doi":"10.1080/09546634.2026.2654112","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1080/09546634.2026.2654112","tag_type":"study_design","value":"Systematic Review and Meta-analysis","value_numeric":null},{"paper_doi":"10.1080/09546634.2026.2654112","tag_type":"study_design","value":"Systematic Review and Meta-Analysis","value_numeric":null},{"paper_doi":"10.1080/09546634.2026.2654112","tag_type":"warning","value":"Effect sizes are reported as standardized mean differences; absolute changes in hair count or density were not provided.","value_numeric":null},{"paper_doi":"10.1080/09546634.2026.2654112","tag_type":"warning","value":"No specific polyphenolic compounds or brand names are named in the abstract; the exact agents evaluated remain unclear from available text.","value_numeric":null},{"paper_doi":"10.1080/09546634.2026.2654112","tag_type":"warning","value":"Specific polyphenolic agents, dosing, and treatment durations varied and were not detailed in the summary.","value_numeric":null},{"paper_doi":"10.1080/09546634.2026.2654112","tag_type":"warning","value":"Substantial heterogeneity limits confidence in pooled effect estimates.","value_numeric":null},{"paper_doi":"10.1080/09546634.2026.2654112","tag_type":"warning","value":"The meta-analysis pools multiple distinct polyphenolic compounds (oral and topical) across different alopecia subtypes, which likely contributes to the noted substantial heterogeneity and limits interpretability of the pooled SMDs.","value_numeric":null},{"paper_doi":"10.1080/09546634.2026.2654112","tag_type":"warning","value":"The PROSPERO registration number (CRD420251230149) could not be independently verified; clinicians should confirm registration status before citing this review as pre-registered evidence.","value_numeric":null}],"summaries":{"limitations":"There was substantial heterogeneity across trials. Long-term and standardized data are lacking.","what_studied":"A systematic review and meta-analysis of randomized, blinded controlled trials tested oral and topical polyphenolic compounds versus controls in adults with non-scarring alopecia. Primary outcomes were trichoscopic hair density and total area hair count.","key_result":"Across 32 RCTs (n=2,183), polyphenolic interventions improved hair density (SMD 0.90; 95% CI 0.51–1.30) and total area hair count (SMD 1.03; 95% CI 0.42–1.63) versus controls; direct comparisons with minoxidil showed no significant difference in overall hair count.","practice_takeaway":"Selected polyphenolic formulations may raise hair density and counts in adults with non-scarring alopecia, but effects vary and they do not outperform minoxidil in head-to-head trials. Use as adjuncts should await more standardized, longer-term studies."}},{"doi":"10.1016/j.jaad.2025.12.105","pmid":"41513100","title":"No elevated risk for osteoporosis or osteopenia among women with androgenetic or frontal fribrosing alopecia treated with 5-alpha reductase inhibitors: A retrospective TriNetX cohort study","journal_title":"Journal of the American Academy of Dermatology","journal_issn":"0190-9622","published_at":"2026-01-10T00:00:00.000Z","url":"https://doi.org/10.1016/j.jaad.2025.12.105","source_score":17,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2026-01-12","doi":"10.1016/j.jaad.2025.12.105","days":"14","issn":"0190-9622","rank":"6","field":"Clinical Medicine","score":"17","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1016/j.jaad.2025.12.105","title":"No elevated risk for osteoporosis or osteopenia among women with androgenetic or frontal fribrosing alopecia treated with 5-alpha reductase inhibitors: A retrospective TriNetX cohort study.","journal":"Journal of the American Academy of Dermatology","methods":"","results":"","abstract":"","keywords":["5-alpha reductase inhibitors","alopecia","androgenetic alopecia","dutasteride","female pattern hair loss","finasteride","frontal fibrosing alopecia","osteopenia","osteoporosis","women"],"pubmed_id":"41513100","conclusions":"","publication_date":"2026-01-10T00:00:00"},"crossref":{"DOI":"10.1016/j.jaad.2025.12.105","URL":"https://doi.org/10.1016/j.jaad.2025.12.105","ISSN":["0190-9622"],"link":[{"URL":"https://api.elsevier.com/content/article/PII:S0190962225035017?httpAccept=text/xml","content-type":"text/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https://api.elsevier.com/content/article/PII:S0190962225035017?httpAccept=text/plain","content-type":"text/plain","content-version":"vor","intended-application":"text-mining"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["No elevated risk for osteoporosis or osteopenia among women with androgenetic or frontal fribrosing alopecia treated with 5-alpha reductase inhibitors: A retrospective TriNetX cohort study"],"author":[{"given":"Daniela","family":"Mendez","sequence":"first","affiliation":[]},{"given":"Marc A.","family":"Hill","sequence":"additional","affiliation":[]},{"given":"Melissa","family":"Piliang","sequence":"additional","affiliation":[]},{"given":"Wilma","family":"Bergfeld","sequence":"additional","affiliation":[]}],"issued":{"date-parts":[[2026,1]]},"member":"78","prefix":"10.1016","source":"Crossref","volume":null,"created":{"date-time":"2026-01-07T08:05:31Z","timestamp":1767773131000,"date-parts":[[2026,1,7]]},"indexed":{"date-time":"2026-01-17T16:00:00Z","timestamp":1768665600099,"date-parts":[[2026,1,17]]},"license":[{"URL":"https://www.elsevier.com/tdm/userlicense/1.0/","start":{"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000,"date-parts":[[2026,1,1]]},"delay-in-days":0,"content-version":"tdm"},{"URL":"https://www.elsevier.com/legal/tdmrep-license","start":{"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000,"date-parts":[[2026,1,1]]},"delay-in-days":0,"content-version":"tdm"}],"subject":[],"abstract":null,"language":"en","relation":{},"resource":{"primary":{"URL":"https://linkinghub.elsevier.com/retrieve/pii/S0190962225035017"}},"subtitle":[],"assertion":[{"name":"publisher","label":"This article is maintained by","value":"Elsevier"},{"name":"articletitle","label":"Article Title","value":"No elevated risk for osteoporosis or osteopenia among women with androgenetic or frontal fribrosing alopecia treated with 5-alpha reductase inhibitors: A retrospective TriNetX cohort study"},{"name":"journaltitle","label":"Journal Title","value":"Journal of the American Academy of Dermatology"},{"name":"articlelink","label":"CrossRef DOI link to publisher maintained version","value":"https://doi.org/10.1016/j.jaad.2025.12.105"},{"name":"content_type","label":"Content Type","value":"article"},{"name":"copyright","label":"Copyright","value":"© 2026 by the American Academy of Dermatology, Inc."}],"deposited":{"date-time":"2026-01-17T04:22:49Z","timestamp":1768623769000,"date-parts":[[2026,1,17]]},"issn-type":[{"type":"print","value":"0190-9622"}],"published":{"date-parts":[[2026,1]]},"publisher":"Elsevier BV","reference":[{"DOI":null,"key":"10.1016/j.jaad.2025.12.105_bib1","year":"2016","issue":"4","author":"Seale","volume":"15","first-page":"414","unstructured":null,"article-title":"Side effects related to 5 α-reductase inhibitor treatment of hair loss in women: a review","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":"10.1016/S0039-128X(00)00136-7","key":"10.1016/j.jaad.2025.12.105_bib2","year":"2000","issue":"12","author":"Zofková","volume":"65","first-page":"857","unstructured":null,"article-title":"The pathophysiological implications of circulating androgens on bone mineral density in a normal female population","journal-title":"Steroids","doi-asserted-by":"crossref"},{"DOI":"10.1186/s12891-018-2076-9","key":"10.1016/j.jaad.2025.12.105_bib3","year":"2018","issue":"1","author":"Antoniou","volume":"19","first-page":"160","unstructured":null,"article-title":"A population-based study of the risk of osteoporosis and fracture with dutasteride and finasteride","journal-title":"BMC Musculoskelet Disord","doi-asserted-by":"crossref"}],"short-title":[],"update-policy":"https://doi.org/10.1016/elsevier_cm_policy","alternative-id":["S0190962225035017"],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"original-title":[],"container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2026,1]]},"reference-count":3,"published-online":null,"references-count":3,"short-container-title":["Journal of the American Academy of Dermatology"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1016/j.jaad.2025.12.105","is_oa":false,"title":"No elevated risk for osteoporosis or osteopenia among women with androgenetic or frontal fribrosing alopecia treated with 5-alpha reductase inhibitors: A retrospective TriNetX cohort study","updated":"2026-01-19T05:56:36+00:00","published_date":"2026-01-01","best_oa_location":null}},"created_at":"2026-01-14T18:30:49.575Z","updated_at":"2026-01-21T12:05:26.220Z","tags":[{"paper_doi":"10.1016/j.jaad.2025.12.105","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2025.12.105","tag_type":"condition","value":"Androgenetic Alopecia","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2025.12.105","tag_type":"condition","value":"Frontal Fibrosing Alopecia","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2025.12.105","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2025.12.105","tag_type":"modality","value":"5-Alpha Reductase Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2025.12.105","tag_type":"sex","value":"female","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2025.12.105","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2025.12.105","tag_type":"warning","value":"Comparator group is not specified in the provided text.","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2025.12.105","tag_type":"warning","value":"Details on adjustments and follow-up duration are unavailable; interpret the finding in context once full methods are reviewed.","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2025.12.105","tag_type":"warning","value":"Only title-level information was available; sample size, comparator groups, and effect estimates were not provided.","value_numeric":null}],"summaries":{"what_studied":"A retrospective TriNetX cohort examined whether women with androgenetic alopecia or frontal fibrosing alopecia treated with 5‑alpha reductase inhibitors have higher rates of osteoporosis or osteopenia.","key_result":"No elevated risk of osteoporosis or osteopenia was observed among these women treated with 5‑alpha reductase inhibitors.","practice_takeaway":"For women with androgenetic or frontal fibrosing alopecia, this cohort found no increased osteoporosis/osteopenia risk with 5‑alpha reductase inhibitors."}},{"doi":"10.1155/dth/6621458","pmid":null,"title":"Long‐Term Efficacy and Safety of Low‐Level Laser Therapy for Androgenetic Alopecia: A 12‐Month Prospective Trial","journal_title":"Dermatologic Therapy","journal_issn":"1396-0296","published_at":"2026-01-08T00:00:00.000Z","url":"https://doi.org/10.1155/dth/6621458","source_score":15,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2026-01-09","doi":"10.1155/dth/6621458","days":"14","issn":"1396-0296","rank":"8","field":"Clinical Medicine","score":"15","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":null,"crossref":{"DOI":"10.1155/dth/6621458","URL":"https://doi.org/10.1155/dth/6621458","ISSN":["1396-0296","1529-8019"],"link":[{"URL":"https://onlinelibrary.wiley.com/doi/pdf/10.1155/dth/6621458","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":"1","score":1,"title":["Long‐Term Efficacy and Safety of Low‐Level Laser Therapy for Androgenetic Alopecia: A 12‐Month Prospective Trial"],"author":[{"given":"Jung-Won","family":"Shin","sequence":"first","affiliation":[]},{"given":"Kyungho","family":"Paik","sequence":"additional","affiliation":[]},{"given":"Jung-Im","family":"Na","sequence":"additional","affiliation":[]},{"given":"Bark-Lynn","family":"Lew","sequence":"additional","affiliation":[]},{"given":"Chang-Hun","family":"Huh","sequence":"additional","affiliation":[]}],"editor":[{"given":"Yung-Tsu","family":"Cho","sequence":"additional","affiliation":[]}],"funder":[{"id":[{"id":"10.13039/501100017634","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/501100017634","name":"LG Electronics","doi-asserted-by":"publisher"}],"issued":{"date-parts":[[2026,1]]},"member":"311","prefix":"10.1155","source":"Crossref","volume":"2026","archive":["Portico"],"created":{"date-time":"2026-01-08T08:55:40Z","timestamp":1767862540000,"date-parts":[[2026,1,8]]},"indexed":{"date-time":"2026-01-08T12:23:00Z","timestamp":1767874980233,"date-parts":[[2026,1,8]]},"license":[{"URL":"http://creativecommons.org/licenses/by/4.0/","start":{"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000,"date-parts":[[2026,1,8]]},"delay-in-days":7,"content-version":"vor"}],"subject":[],"abstract":"$31","language":"en","relation":{},"resource":{"primary":{"URL":"https://onlinelibrary.wiley.com/doi/10.1155/dth/6621458"}},"subtitle":[],"assertion":[{"name":"received","group":{"name":"publication_history","label":"Publication History"},"label":"Received","order":0,"value":"2025-04-21"},{"name":"accepted","group":{"name":"publication_history","label":"Publication History"},"label":"Accepted","order":2,"value":"2025-12-17"},{"name":"published","group":{"name":"publication_history","label":"Publication History"},"label":"Published","order":3,"value":"2026-01-08"}],"deposited":{"date-time":"2026-01-08T08:55:45Z","timestamp":1767862545000,"date-parts":[[2026,1,8]]},"issn-type":[{"type":"print","value":"1396-0296"},{"type":"electronic","value":"1529-8019"}],"published":{"date-parts":[[2026,1]]},"publisher":"Wiley","reference":[{"DOI":"10.1007/s40265-023-01880-x","key":"e_1_2_9_1_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1046/j.1365-2133.2001.04289.x","key":"e_1_2_9_2_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jdin.2023.07.005","key":"e_1_2_9_3_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3109/09546634.2013.813011","key":"e_1_2_9_4_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/dth.12246","key":"e_1_2_9_5_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1080/09546634.2022.2109567","key":"e_1_2_9_6_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_9_7_2","year":"2019","issue":null,"author":"Lee S.","volume":"99","first-page":"12","unstructured":null,"article-title":"Adverse Sexual Effects of Treatment With Finasteride or Dutasteride for Male Androgenetic Alopecia: A Systematic Review and Meta-Analysis","journal-title":"Acta Dermato-Venereologica","doi-asserted-by":null},{"DOI":"10.4103/0378-6323.51273","key":"e_1_2_9_8_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1610-0387.2007.06295.x","key":"e_1_2_9_9_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/php.12864","key":"e_1_2_9_10_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_9_11_2","year":"1968","issue":null,"author":"Mester E.","volume":"9","first-page":"621","unstructured":null,"article-title":"The Effect of Laser Beams on the Growth of Hair in Mice","journal-title":"Radiobiologia, Radiotherapia","doi-asserted-by":null},{"DOI":"10.1109/embc.2017.8037634","key":"e_1_2_9_12_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.det.2012.08.018","key":"e_1_2_9_13_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s40257-013-0060-6","key":"e_1_2_9_14_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.4103/jcas.jcas_218_20","key":"e_1_2_9_15_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_9_16_2","year":"2021","issue":null,"author":"Lueangarun S.","volume":"14","first-page":"E64","unstructured":null,"article-title":"A Systematic Review and Meta-Analysis of Randomized Controlled Trials of United States Food and Drug Administration-Approved, Home-Use, Low-Level Light/Laser Therapy Devices for Pattern Hair Loss: Device Design and Technology","journal-title":"Journal of Clinical and Aesthetic Dermatology","doi-asserted-by":null},{"DOI":"10.1111/dsu.12200","key":"e_1_2_9_17_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.2165/00044011-200929050-00001","key":"e_1_2_9_18_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1080/14764172.2017.1400170","key":"e_1_2_9_19_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.25289/ml.2020.9.2.150","key":"e_1_2_9_20_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s10103-020-03159-z","key":"e_1_2_9_21_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1080/09546630310004171","key":"e_1_2_9_22_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s10103-018-02699-9","key":"e_1_2_9_23_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1159/000509001","key":"e_1_2_9_24_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.4103/ijt.ijt_5_22","key":"e_1_2_9_25_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.4103/ijdvl.ijdvl_1156_16","key":"e_1_2_9_26_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"}],"short-title":[],"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"update-policy":"https://doi.org/10.1002/crossmark_policy","alternative-id":["10.1155/dth/6621458"],"article-number":"6621458","content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"original-title":[],"container-title":["Dermatologic Therapy"],"published-print":{"date-parts":[[2026,1]]},"reference-count":26,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2026,1,8]]},"references-count":26,"short-container-title":["Dermatologic Therapy"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1155/dth/6621458","is_oa":true,"title":"Long‐Term Efficacy and Safety of Low‐Level Laser Therapy for Androgenetic Alopecia: A 12‐Month Prospective Trial","updated":"2026-01-10T04:46:20+00:00","published_date":"2026-01-01","best_oa_location":{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1155/dth/6621458","pmh_id":null,"url_for_pdf":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1155/dth/6621458","url_for_landing_page":"https://doi.org/10.1155/dth/6621458"}}},"created_at":"2026-01-14T18:30:49.575Z","updated_at":"2026-01-20T15:55:50.695Z","tags":[{"paper_doi":"10.1155/dth/6621458","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1155/dth/6621458","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1155/dth/6621458","tag_type":"condition","value":"Androgenetic Alopecia","value_numeric":null},{"paper_doi":"10.1155/dth/6621458","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1155/dth/6621458","tag_type":"level_of_evidence","value":"6","value_numeric":null},{"paper_doi":"10.1155/dth/6621458","tag_type":"modality","value":"Low-Level Laser Therapy","value_numeric":null},{"paper_doi":"10.1155/dth/6621458","tag_type":"sample_size","value":"n=68","value_numeric":68},{"paper_doi":"10.1155/dth/6621458","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1155/dth/6621458","tag_type":"study_design","value":"Single-Arm Interventional Study","value_numeric":null},{"paper_doi":"10.1155/dth/6621458","tag_type":"warning","value":"Design classification is approximate: prospective, open‑label, single‑arm device trial without a control group.","value_numeric":null},{"paper_doi":"10.1155/dth/6621458","tag_type":"warning","value":"Device brand/model is not specified in the abstract, which may affect generalizability.","value_numeric":null},{"paper_doi":"10.1155/dth/6621458","tag_type":"warning","value":"Primary outcome is not clearly prespecified in the abstract; multiple efficacy measures are reported.","value_numeric":null}],"summaries":{"what_studied":"A 12‑month, prospective open‑label trial tested a home‑use helmet low‑level laser therapy (646–675 nm), used 3 times per week for 20 minutes over 48 weeks, in 68 adults (51 men, 17 women) with mild to severe androgenetic alopecia. Outcomes included phototrichogram hair density and shaft thickness, blinded global photographic assessments, patient‑reported satisfaction, adherence, and adverse events.","key_result":"Hair density rose from 99.2±27.7 to 124.2±33.1 hairs/cm² at 48 weeks (mean change +25.0±28.1; p<0.0001), and mean shaft thickness increased from 65.1±11.8 to 74.9±12.6 μm (p<0.0001). By Week 48, 59% were rated improved on global photographs, >85% reported satisfaction, no device‑related adverse events occurred, and adherence was high.","limitations":"Single‑arm, open‑label design without a control group limits causal inference and comparison to standard therapies. Findings reflect a specific helmet device and dosing protocol, and the abstract does not prespecify a primary outcome.","practice_takeaway":"For adults with androgenetic alopecia, a home‑use helmet LLLT regimen (3 times/week, 20 minutes) over 12 months produced moderate gains in hair count (~+25 hairs/cm²) and ~15% thicker shafts with no reported device‑related harms in this uncontrolled study. Discuss as a well‑tolerated option while counseling patients about the limited comparative evidence."}},{"doi":"10.1111/jocd.70483","pmid":"41051009","title":"Relative Efficacy of Conventional Monotherapies and Select Nonconventional, Over‐the‐Counter Products for Male Androgenetic Alopecia: A Network Meta‐Analysis Study","journal_title":"Journal of Cosmetic Dermatology","journal_issn":"1473-2130","published_at":"2025-10-06T00:00:00.000Z","url":"https://doi.org/10.1111/jocd.70483","source_score":11,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2025-10-12","doi":"10.1111/jocd.70483","days":"14","issn":"1473-2130","rank":"7","field":"Clinical Medicine","score":"11","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1111/jocd.70483","title":"Relative Efficacy of Conventional Monotherapies and Select Nonconventional, Over-the-Counter Products for Male Androgenetic Alopecia: A Network Meta-Analysis Study.","journal":"Journal of cosmetic dermatology","methods":"","results":"","abstract":"$32","keywords":[],"pubmed_id":"41051009","conclusions":"","publication_date":"2025-10-06T00:00:00"},"crossref":{"DOI":"10.1111/jocd.70483","URL":"https://doi.org/10.1111/jocd.70483","ISSN":["1473-2130","1473-2165"],"link":[{"URL":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/jocd.70483","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":"10","score":1,"title":["Relative Efficacy of Conventional Monotherapies and Select Nonconventional, Over‐the‐Counter Products for Male Androgenetic Alopecia: A Network Meta‐Analysis Study"],"author":[{"given":"Aditya K.","family":"Gupta","sequence":"first","affiliation":[{"name":"Mediprobe Research Inc. London Ontario Canada"},{"name":"Division of Dermatology, Department of Medicine University of Toronto School of Medicine Toronto Ontario Canada"}]},{"given":"Mary A.","family":"Bamimore","sequence":"additional","affiliation":[{"name":"Mediprobe Research Inc. London Ontario Canada"}]},{"given":"Mesbah","family":"Talukder","sequence":"additional","affiliation":[{"name":"School of Pharmacy BRAC University Dhaka Bangladesh"}]}],"issued":{"date-parts":[[2025,10]]},"member":"311","prefix":"10.1111","source":"Crossref","volume":"24","archive":["Portico"],"created":{"date-time":"2025-10-06T23:33:55Z","timestamp":1759793635000,"date-parts":[[2025,10,6]]},"indexed":{"date-time":"2025-10-07T00:56:00Z","timestamp":1759798560404,"date-parts":[[2025,10,7]]},"license":[{"URL":"http://creativecommons.org/licenses/by/4.0/","start":{"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000,"date-parts":[[2025,10,6]]},"delay-in-days":5,"content-version":"vor"}],"subject":[],"abstract":"$33","language":"en","relation":{},"resource":{"primary":{"URL":"https://onlinelibrary.wiley.com/doi/10.1111/jocd.70483"}},"subtitle":[],"assertion":[{"name":"received","group":{"name":"publication_history","label":"Publication History"},"label":"Received","order":0,"value":"2025-07-29"},{"name":"accepted","group":{"name":"publication_history","label":"Publication History"},"label":"Accepted","order":2,"value":"2025-09-26"},{"name":"published","group":{"name":"publication_history","label":"Publication History"},"label":"Published","order":3,"value":"2025-10-06"}],"deposited":{"date-time":"2025-10-06T23:34:06Z","timestamp":1759793646000,"date-parts":[[2025,10,6]]},"issn-type":[{"type":"print","value":"1473-2130"},{"type":"electronic","value":"1473-2165"}],"published":{"date-parts":[[2025,10]]},"publisher":"Wiley","reference":[{"DOI":"10.1111/dth.12390","key":"e_1_2_11_2_1","year":"2016","issue":"6","author":"Rossi A.","volume":"29","first-page":"424","unstructured":null,"article-title":"Multi‐Therapies in Androgenetic Alopecia: Review and Clinical Experiences","journal-title":"Dermatologic Therapy","doi-asserted-by":"crossref"},{"DOI":"10.1111/bjd.12443","key":"e_1_2_11_3_1","year":"2013","issue":"4","author":"Heilmann S.","volume":"169","first-page":"927","unstructured":null,"article-title":"Evidence for a Polygenic Contribution to Androgenetic Alopecia","journal-title":"British Journal of Dermatology","doi-asserted-by":"crossref"},{"DOI":"10.1067/mjd.2001.117426","key":"e_1_2_11_4_1","year":"2001","issue":"3","author":"Olsen E. A.","volume":"45","first-page":"S70","unstructured":null,"article-title":"Female Pattern Hair Loss","journal-title":"Journal of the American Academy of Dermatology","doi-asserted-by":"crossref"},{"DOI":"10.2147/CCID.S271013","key":"e_1_2_11_5_1","year":"2020","issue":null,"author":"Majeed M.","volume":"13","first-page":"691","unstructured":null,"article-title":"Clinical Study to Evaluate the Efficacy and Safety of a Hair Serum Product in Healthy Adult Male and Female Volunteers With Hair Fall","journal-title":"Clinical, Cosmetic and Investigational Dermatology","doi-asserted-by":"crossref"},{"DOI":"10.1046/j.1365-2133.1999.03030.x","key":"e_1_2_11_6_1","year":"1999","issue":"3","author":"Cash T. F.","volume":"141","first-page":"398","unstructured":null,"article-title":"The Psychosocial Consequences of Androgenetic Alopecia: A Review of the Research Literature","journal-title":"British Journal of Dermatology","doi-asserted-by":"crossref"},{"DOI":"10.1080/13548506.2023.2242049","key":"e_1_2_11_7_1","year":"2024","issue":"4","author":"Frith H.","volume":"29","first-page":"822","unstructured":null,"article-title":"Psychosocial Impact of Androgenetic Alopecia on Men: A Systematic Review and Meta‐Analysis","journal-title":"Psychology, Health & Medicine","doi-asserted-by":"crossref"},{"DOI":"10.1080/13543784.2017.1353598","key":"e_1_2_11_8_1","year":"2017","issue":"8","author":"Guo H.","volume":"26","first-page":"917","unstructured":null,"article-title":"Experimental and Early Investigational Drugs for Androgenetic Alopecia","journal-title":"Expert Opinion on Investigational Drugs","doi-asserted-by":"crossref"},{"DOI":null,"key":"e_1_2_11_9_1","year":"2022","issue":"3","author":"Ring C.","volume":"15","first-page":"26","unstructured":null,"article-title":"Nutraceuticals for Androgenetic Alopecia","journal-title":"Journal of Clinical and Aesthetic Dermatology","doi-asserted-by":null},{"DOI":"10.1016/j.jaad.2008.07.001","key":"e_1_2_11_10_1","year":"2008","issue":"4","author":"Rogers N. E.","volume":"59","first-page":"547","unstructured":null,"article-title":"Medical Treatments for Male and Female Pattern Hair Loss","journal-title":"Journal of the American Academy of Dermatology","doi-asserted-by":"crossref"},{"DOI":null,"key":"e_1_2_11_11_1","year":"2022","issue":null,"author":"Anastassakis K.","volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1111/dth.12647","key":"e_1_2_11_12_1","year":"2019","issue":"2","author":"Andy G.","volume":"32","first-page":null,"unstructured":null,"article-title":"Controversies in the Treatment of Androgenetic Alopecia: The History of Finasteride","journal-title":"Dermatologic Therapy","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.tibtech.2022.12.020","key":"e_1_2_11_13_1","year":"2023","issue":"6","author":"Castro A. R.","volume":"41","first-page":"731","unstructured":null,"article-title":"The Booming Business of Hair Loss","journal-title":"Trends in Biotechnology","doi-asserted-by":"crossref"},{"DOI":"10.2147/CCID.S470989","key":"e_1_2_11_14_1","year":"2024","issue":null,"author":"Bin Rubaian N. F.","volume":"17","first-page":"2495","unstructured":null,"article-title":"An Overview of Commonly Used Natural Alternatives for the Treatment of Androgenetic Alopecia, With Special Emphasis on Rosemary Oil","journal-title":"Clinical, Cosmetic and Investigational Dermatology","doi-asserted-by":"crossref"},{"DOI":"10.37766/inplasy2025.6.0102","key":"e_1_2_11_15_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"A.GuptaandM.Bamimore “The Comparative Effectiveness of Prescription and Selected Alternative Therapies for Pattern Hair Loss: Protocol for a Multiple Treatment Comparison Meta‐Analysis ” (2025).","article-title":null,"journal-title":null,"doi-asserted-by":"crossref"},{"DOI":"10.7326/M14-2385","key":"e_1_2_11_16_1","year":"2015","issue":"11","author":"Hutton B.","volume":"162","first-page":"777","unstructured":null,"article-title":"The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta‐Analyses of Health Care Interventions: Checklist and Explanations","journal-title":"Annals of Internal Medicine","doi-asserted-by":"crossref"},{"DOI":"10.1186/s13643-024-02619-9","key":"e_1_2_11_17_1","year":"2024","issue":"1","author":"Forbes C.","volume":"13","first-page":"206","unstructured":null,"article-title":"Automation of Duplicate Record Detection for Systematic Reviews: Deduplicator","journal-title":"Systematic Reviews","doi-asserted-by":"crossref"},{"DOI":"10.1002/jrsm.1411","key":"e_1_2_11_18_1","year":"2021","issue":"1","author":"McGuinness L. A.","volume":"12","first-page":"55","unstructured":null,"article-title":"Risk‐Of‐Bias VISualization (Robvis): An R Package and Shiny Web App for Visualizing Risk‐Of‐Bias Assessments","journal-title":"Research Synthesis Methods","doi-asserted-by":"crossref"},{"DOI":"10.1002/jrsm.1167","key":"e_1_2_11_19_1","year":"2016","issue":"1","author":"Valkenhoef G.","volume":"7","first-page":"80","unstructured":null,"article-title":"Automated Generation of Node‐Splitting Models for Assessment of Inconsistency in Network Meta‐Analysis","journal-title":"Research Synthesis Methods","doi-asserted-by":"crossref"},{"DOI":"10.1002/jrsm.1428","key":"e_1_2_11_20_1","year":"2021","issue":"1","author":"Seo M.","volume":"12","first-page":"86","unstructured":null,"article-title":"The Kilim Plot: A Tool for Visualizing Network Meta‐Analysis Results for Multiple Outcomes","journal-title":"Research Synthesis Methods","doi-asserted-by":"crossref"},{"DOI":"10.4103/ijt.ijt_72_22","key":"e_1_2_11_21_1","year":"2023","issue":"2","author":"Bharadwaj A. V.","volume":"15","first-page":"56","unstructured":null,"article-title":"Comparative Efficacy of Topical Finasteride (0.25%) in Combination With Minoxidil (5%) Against 5% Minoxidil or 0.25% Finasteride Alone in Male Androgenetic Alopecia: A Pilot, Randomized Open‐Label Study","journal-title":"International Journal of Trichology","doi-asserted-by":"crossref"},{"DOI":"10.1111/jocd.15953","key":"e_1_2_11_22_1","year":"2024","issue":"2","author":"Rossi A.","volume":"23","first-page":"502","unstructured":null,"article-title":"Efficacy of the Association of Topical Minoxidil and Topical Finasteride Compared to Their Use in Monotherapy in Men With Androgenetic Alopecia: A Prospective, Randomized, Controlled, Assessor Blinded, 3‐Arm, Pilot Trial","journal-title":"Journal of Cosmetic Dermatology","doi-asserted-by":"crossref"},{"DOI":"10.1111/ics.12764","key":"e_1_2_11_23_1","year":"2022","issue":"2","author":"Hashimoto M.","volume":"44","first-page":"154","unstructured":null,"article-title":"Effects of Watercress Extract Fraction on R‐Spondin 1‐Mediated Growth of Human Hair","journal-title":"International Journal of Cosmetic Science","doi-asserted-by":"crossref"},{"DOI":"10.1111/jdv.17738","key":"e_1_2_11_24_1","year":"2022","issue":"2","author":"Piraccini B. M.","volume":"36","first-page":"286","unstructured":null,"article-title":"Efficacy and Safety of Topical Finasteride Spray Solution for Male Androgenetic Alopecia: A Phase III, Randomised, Controlled Clinical Trial","journal-title":"Journal of the European Academy of Dermatology and Venereology","doi-asserted-by":"crossref"},{"DOI":"10.1007/s13555-020-00448-x","key":"e_1_2_11_25_1","year":"2020","issue":"6","author":"Panchaprateep R.","volume":"10","first-page":"1345","unstructured":null,"article-title":"Efficacy and Safety of Oral Minoxidil 5 Mg Once Daily in the Treatment of Male Patients With Androgenetic Alopecia: An Open‐Label and Global Photographic Assessment","journal-title":"Dermatology and Therapy (Heidelberg)","doi-asserted-by":"crossref"},{"DOI":"10.4103/ijdvl.IJDVL_589_18","key":"e_1_2_11_26_1","year":"2020","issue":"2","author":"Singh S. K.","volume":"86","first-page":"150","unstructured":null,"article-title":"Comparison of Efficacy of Platelet‐Rich Plasma Therapy With or Without Topical 5% Minoxidil in Male‐Type Baldness: A Randomized, Double‐Blind Placebo Control Trial","journal-title":"Indian Journal of Dermatology, Venereology and Leprology","doi-asserted-by":"crossref"},{"DOI":"10.4103/0378-6323.188652","key":"e_1_2_11_27_1","year":"2017","issue":"1","author":"Shanshanwal S. J.","volume":"83","first-page":"47","unstructured":null,"article-title":"Superiority of Dutasteride Over Finasteride in Hair Regrowth and Reversal of Miniaturization in Men With Androgenetic Alopecia: A Randomized Controlled Open‐Label, Evaluator‐Blinded Study","journal-title":"Indian Journal of Dermatology, Venereology and Leprology","doi-asserted-by":"crossref"},{"DOI":"10.1111/jocd.12265","key":"e_1_2_11_28_1","year":"2016","issue":"4","author":"Ablon G.","volume":"15","first-page":"358","unstructured":null,"article-title":"A 6‐Month, Randomized, Double‐Blind, Placebo‐Controlled Study Evaluating the Ability of a Marine Complex Supplement to Promote Hair Growth in Men With Thinning Hair","journal-title":"Journal of Cosmetic Dermatology","doi-asserted-by":"crossref"},{"DOI":null,"key":"e_1_2_11_29_1","year":"2015","issue":"1","author":"Panahi Y.","volume":"13","first-page":"15","unstructured":null,"article-title":"Rosemary Oil vs Minoxidil 2% for the Treatment of Androgenetic Alopecia: A Randomized Comparative Trial","journal-title":"Skinmed","doi-asserted-by":null},{"DOI":"10.1016/j.jaad.2013.10.049","key":"e_1_2_11_30_1","year":"2014","issue":"3","author":"Gubelin Harcha W.","volume":"70","first-page":"489","unstructured":null,"article-title":"A Randomized, Active‐ and Placebo‐Controlled Study of the Efficacy and Safety of Different Doses of Dutasteride Versus Placebo and Finasteride in the Treatment of Male Subjects With Androgenetic Alopecia","journal-title":"Journal of the American Academy of Dermatology","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2009.09.018","key":"e_1_2_11_31_1","year":"2010","issue":"2","author":"Eun H. C.","volume":"63","first-page":"252","unstructured":null,"article-title":"Efficacy, Safety, and Tolerability of Dutasteride 0.5 Mg Once Daily in Male Patients With Male Pattern Hair Loss: A Randomized, Double‐Blind, Placebo‐Controlled, Phase III Study","journal-title":"Journal of the American Academy of Dermatology","doi-asserted-by":"crossref"},{"DOI":"10.4103/0378-6323.45220","key":"e_1_2_11_32_1","year":"2009","issue":"1","author":"Hajheydari Z.","volume":"75","first-page":"47","unstructured":null,"article-title":"Comparing the Therapeutic Effects of Finasteride Gel and Tablet in Treatment of the Androgenetic Alopecia","journal-title":"Indian Journal of Dermatology, Venereology and Leprology","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1473-2165.2005.00199.x","key":"e_1_2_11_33_1","year":"2005","issue":"4","author":"Takahashi T.","volume":"4","first-page":"245","unstructured":null,"article-title":"Investigation of the Topical Application of Procyanidin Oligomers From Apples to Identify Their Potential Use as a Hair‐Growing Agent","journal-title":"Journal of Cosmetic Dermatology","doi-asserted-by":"crossref"},{"DOI":null,"key":"e_1_2_11_34_1","year":"1999","issue":"4","author":"Roberts J. L.","volume":"41","first-page":"555","unstructured":null,"article-title":"Clinical Dose Ranging Studies With Finasteride, a Type 2 5α‐Reductase Inhibitor, in Men With Male Pattern Hair Loss","journal-title":"Journal of the American Academy of Dermatology","doi-asserted-by":null},{"DOI":"10.1016/S0190-9622(98)70007-6","key":"e_1_2_11_35_1","year":"1998","issue":"4","author":"Kaufman K. D.","volume":"39","first-page":"578","unstructured":null,"article-title":"Finasteride in the Treatment of Men With Androgenetic Alopecia. Finasteride Male Pattern Hair Loss Study Group","journal-title":"Journal of the American Academy of Dermatology","doi-asserted-by":"crossref"},{"DOI":"10.1159/000017954","key":"e_1_2_11_36_1","year":"1998","issue":"4","author":"Pierard‐Franchimont C.","volume":"196","first-page":"474","unstructured":null,"article-title":"Ketoconazole Shampoo: Effect of Long‐Term Use in Androgenic Alopecia","journal-title":"Dermatology","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1742-1241.1999.tb11660.x","key":"e_1_2_11_37_1","year":"1999","issue":"1","author":"Rushton D. H.","volume":"53","first-page":"50","unstructured":null,"article-title":"Androgenetic Alopecia in Men: The Scale of the Problem and Prospects for Treatment","journal-title":"International Journal of Clinical Practice","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1365-4362.1988.tb00006.x","key":"e_1_2_11_38_1","year":"1988","issue":null,"author":"Anderson C.","volume":"27","first-page":"447","unstructured":null,"article-title":"Topical Minoxidil in Androgenetic Alopecia Scandinavian and Middle East Experience","journal-title":"International Journal of Dermatology","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1365-4362.1988.tb00004.x","key":"e_1_2_11_39_1","year":"1988","issue":null,"author":"Dutrée‐Meulenberg R.","volume":"27","first-page":"435","unstructured":null,"article-title":"Treatment of Male Pattern Alopecia Using Topical Minoxidil in The Netherlands","journal-title":"International Journal of Dermatology","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1365-4362.1988.tb00003.x","key":"e_1_2_11_40_1","year":"1988","issue":null,"author":"Petzoldt D.","volume":"27","first-page":"430","unstructured":null,"article-title":"The German Double‐Blind Placebo‐Controlled Evaluation of Topical Minoxidil Solution in the Treatment of Early Male Pattern Baldness","journal-title":"International Journal of Dermatology","doi-asserted-by":"crossref"},{"DOI":"10.1159/000248902","key":"e_1_2_11_41_1","year":"1987","issue":"2","author":"Civatte J.","volume":"175","first-page":"42","unstructured":null,"article-title":"2% Topical Minoxidil Solution in Male‐Pattern Baldness: Preliminary European Results","journal-title":"Dermatologica","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0190-9622(86)70138-2","key":"e_1_2_11_42_1","year":"1986","issue":"1","author":"Olsen E. A.","volume":"15","first-page":"30","unstructured":null,"article-title":"Dose‐Response Study of Topical Minoxidil in Male Pattern Baldness","journal-title":"Journal of the American Academy of Dermatology","doi-asserted-by":"crossref"},{"DOI":"10.1111/ajd.12352","key":"e_1_2_11_43_1","year":"2016","issue":"3","author":"Wessagowit V.","volume":"57","first-page":"e76","unstructured":null,"article-title":"Treatment of Male Androgenetic Alopecia With Topical Products Containing S Erenoa Repens Extract","journal-title":"Australasian Journal of Dermatology","doi-asserted-by":"crossref"},{"DOI":"10.4103/0974-7753.111199","key":"e_1_2_11_44_1","year":"2012","issue":"4","author":"Fischer T. W.","volume":"4","first-page":"236","unstructured":null,"article-title":"Topical Melatonin for Treatment of Androgenetic Alopecia","journal-title":"International Journal of Trichology","doi-asserted-by":"crossref"},{"DOI":"10.18549/PharmPract.2017.01.943","key":"e_1_2_11_45_1","year":"2017","issue":"1","author":"Tonin F. S.","volume":"15","first-page":"943","unstructured":null,"article-title":"Network Meta‐Analysis: A Technique to Gather Evidence From Direct and Indirect Comparisons","journal-title":"Pharmacy Practice (Granada)","doi-asserted-by":"crossref"},{"DOI":null,"key":"e_1_2_11_46_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"FDA “FDA Alerts Health Care Providers Compounders and Consumers of Potential Risks Associated With Compounded Topical Finasteride Products ” (2025) https://www.drugs.com/fda/fda‐alerts‐health‐care‐providers‐compounders‐consumers‐potential‐risks‐associated‐compounded‐14740.html.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.25259/jcas_44_23","key":"e_1_2_11_47_1","year":"2024","issue":"3","author":"Nirmal B.","volume":"17","first-page":"189","unstructured":null,"article-title":"Efficacy and Safety of Microneedling Radiofrequency in Patterned Hair Loss","journal-title":"Journal of Cutaneous and Aesthetic Surgery","doi-asserted-by":"crossref"},{"DOI":null,"key":"e_1_2_11_48_1","year":"2016","issue":null,"author":"Koyama T.","volume":"16","first-page":null,"unstructured":null,"article-title":"Standardized Scalp Massage Results in Increased Hair Thickness by Inducing Stretching Forces to Dermal Papilla Cells in the Subcutaneous Tissue","journal-title":"Eplasty","doi-asserted-by":null},{"DOI":null,"key":"e_1_2_11_49_1","year":"2021","issue":"11","author":"Lueangarun S.","volume":"14","first-page":"E64","unstructured":null,"article-title":"A Systematic Review and Meta‐Analysis of Randomized Controlled Trials of United States Food and Drug Administration‐Approved, Home‐Use, Low‐Level Light/Laser Therapy Devices for Pattern Hair Loss: Device Design and Technology","journal-title":"Journal of Clinical and Aesthetic Dermatology","doi-asserted-by":null},{"DOI":"10.1111/dth.15323","key":"e_1_2_11_50_1","year":"2022","issue":"4","author":"Gupta A. K.","volume":"35","first-page":null,"unstructured":null,"article-title":"Natural Products for Male Androgenetic Alopecia","journal-title":"Dermatologic Therapy","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0944-7113(00)80040-9","key":"e_1_2_11_51_1","year":"2000","issue":"6","author":"Kamimura A.","volume":"7","first-page":"529","unstructured":null,"article-title":"Investigation of Topical Application of Procyanidin B‐2 From Apple to Identify Its Potential Use as a Hair Growing Agent","journal-title":"Phytomedicine","doi-asserted-by":"crossref"},{"DOI":"10.1111/jocd.14299","key":"e_1_2_11_52_1","year":"2022","issue":"1","author":"Dhurat R.","volume":"21","first-page":"343","unstructured":null,"article-title":"SULT1A1 (Minoxidil Sulfotransferase) Enzyme Booster Significantly Improves Response to Topical Minoxidil for Hair Regrowth","journal-title":"Journal of Cosmetic Dermatology","doi-asserted-by":"crossref"},{"DOI":"10.1111/jdv.16765","key":"e_1_2_11_53_1","year":"2021","issue":"1","author":"Ramos P. M.","volume":"35","first-page":"e24","unstructured":null,"article-title":"Minoxidil Sulfotransferase Enzyme (SULT1A1) Genetic Variants Predicts Response to Oral Minoxidil Treatment for Female Pattern Hair Loss","journal-title":"Journal of the European Academy of Dermatology and Venereology","doi-asserted-by":"crossref"},{"DOI":"10.5114/ada.2020.99947","key":"e_1_2_11_54_1","year":"2022","issue":"3","author":"Pietrauszka K.","volume":"39","first-page":"472","unstructured":null,"article-title":"Sulfotransferase SULT1A1 Activity in Hair Follicle, a Prognostic Marker of Response to the Minoxidil Treatment in Patients With Androgenetic Alopecia: A Review","journal-title":"Postepy Dermatologii I Alergologii","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamadermatol.2021.5743","key":"e_1_2_11_55_1","year":"2022","issue":"3","author":"Gupta A. K.","volume":"158","first-page":"266","unstructured":null,"article-title":"Relative Efficacy of Minoxidil and the 5‐Alpha Reductase Inhibitors in Androgenetic Alopecia Treatment of Male Patients: A Network Meta‐Analysis","journal-title":"JAMA Dermatology","doi-asserted-by":"crossref"},{"DOI":"10.1159/000538621","key":"e_1_2_11_56_1","year":"2024","issue":"4","author":"Starace M. V. R.","volume":"10","first-page":"293","unstructured":null,"article-title":"The Comparative Effects of Monotherapy With Topical Minoxidil, Oral Finasteride, and Topical Finasteride in Postmenopausal Women With Pattern Hair Loss: A Retrospective Cohort Study","journal-title":"Skin Appendage Disorders","doi-asserted-by":"crossref"},{"DOI":"10.1111/jocd.13976","key":"e_1_2_11_57_1","year":"2021","issue":"9","author":"Ibrahim I. M.","volume":"20","first-page":"2867","unstructured":null,"article-title":"Pumpkin Seed Oil vs. Minoxidil 5% Topical Foam for the Treatment of Female Pattern Hair Loss: A Randomized Comparative Trial","journal-title":"Journal of Cosmetic Dermatology","doi-asserted-by":"crossref"},{"DOI":"10.1248/bpb.b15-00387","key":"e_1_2_11_58_1","year":"2015","issue":"12","author":"Choi J. S.","volume":"38","first-page":"1856","unstructured":null,"article-title":"Safety and Efficacy of Rice Bran Supercritical CO2 Extract for Hair Growth in Androgenic Alopecia: A 16‐Week Double‐Blind Randomized Controlled Trial","journal-title":"Biological & Pharmaceutical Bulletin","doi-asserted-by":"crossref"},{"DOI":"10.1007/978-3-031-74314-6","key":"e_1_2_11_59_1","year":"2024","issue":null,"author":"Panagotacos P. J.","volume":null,"first-page":"1","unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"crossref"}],"short-title":[],"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"update-policy":"https://doi.org/10.1002/crossmark_policy","alternative-id":["10.1111/jocd.70483"],"article-number":"e70483","content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"original-title":[],"container-title":["Journal of Cosmetic Dermatology"],"published-print":{"date-parts":[[2025,10]]},"reference-count":58,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2025,10,6]]},"references-count":58,"short-container-title":["J of Cosmetic Dermatology"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1111/jocd.70483","is_oa":true,"title":"Relative Efficacy of Conventional Monotherapies and Select Nonconventional, Over‐the‐Counter Products for Male Androgenetic Alopecia: A Network Meta‐Analysis Study","updated":"2025-10-11T00:07:04+00:00","published_date":"2025-10-01","best_oa_location":{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jocd.70483","pmh_id":null,"url_for_pdf":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jocd.70483","url_for_landing_page":"https://doi.org/10.1111/jocd.70483"}}},"created_at":"2025-10-13T07:32:37.233Z","updated_at":"2025-10-19T07:07:31.491Z","tags":[{"paper_doi":"10.1111/jocd.70483","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1111/jocd.70483","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1111/jocd.70483","tag_type":"condition","value":"Androgenetic Alopecia","value_numeric":null},{"paper_doi":"10.1111/jocd.70483","tag_type":"generic","value":"dutasteride","value_numeric":null},{"paper_doi":"10.1111/jocd.70483","tag_type":"generic","value":"finasteride","value_numeric":null},{"paper_doi":"10.1111/jocd.70483","tag_type":"generic","value":"ketoconazole","value_numeric":null},{"paper_doi":"10.1111/jocd.70483","tag_type":"generic","value":"melatonin","value_numeric":null},{"paper_doi":"10.1111/jocd.70483","tag_type":"generic","value":"minoxidil","value_numeric":null},{"paper_doi":"10.1111/jocd.70483","tag_type":"generic","value":"procyanidin","value_numeric":null},{"paper_doi":"10.1111/jocd.70483","tag_type":"generic","value":"rosemary oil","value_numeric":null},{"paper_doi":"10.1111/jocd.70483","tag_type":"generic","value":"saw palmetto","value_numeric":null},{"paper_doi":"10.1111/jocd.70483","tag_type":"generic","value":"watercress extract","value_numeric":null},{"paper_doi":"10.1111/jocd.70483","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1111/jocd.70483","tag_type":"modality","value":"5-Alpha Reductase Inhibitor","value_numeric":null},{"paper_doi":"10.1111/jocd.70483","tag_type":"modality","value":"Botanical","value_numeric":null},{"paper_doi":"10.1111/jocd.70483","tag_type":"modality","value":"Nutraceutical","value_numeric":null},{"paper_doi":"10.1111/jocd.70483","tag_type":"modality","value":"Topical Minoxidil","value_numeric":null},{"paper_doi":"10.1111/jocd.70483","tag_type":"sex","value":"male","value_numeric":null},{"paper_doi":"10.1111/jocd.70483","tag_type":"study_design","value":"Network Meta-Analysis","value_numeric":null},{"paper_doi":"10.1111/jocd.70483","tag_type":"warning","value":"A fixed‑effect model was used; between‑study heterogeneity was not modeled.","value_numeric":null},{"paper_doi":"10.1111/jocd.70483","tag_type":"warning","value":"Some node‑splitting comparisons showed p<0.05 (inconsistency) despite the statement that most comparisons were consistent.","value_numeric":null},{"paper_doi":"10.1111/jocd.70483","tag_type":"warning","value":"The manuscript alternately cites 24 vs 25 included trials, creating uncertainty about the exact study count.","value_numeric":null}],"summaries":{"what_studied":"A Bayesian fixed‑effect network meta‑analysis compared eight conventional monotherapies with seven over‑the‑counter alternatives for male androgenetic alopecia, using 24‑week change in total hair density (hairs/cm²) as the outcome after searches of PubMed and Scopus on April 30, 2025.","key_result":"Dutasteride 0.5 mg (oral) ranked highest (SUCRA 95.8% base; 94% severity‑adjusted). Versus control, network estimates showed mean hair density gains at 24 weeks for minoxidil 5% topical: +20.0 hairs/cm² (95% CrI 3.7 to 41.0), dutasteride 0.5 mg oral: +19.0 (9.5 to 28.0), finasteride 0.25% topical: +15.0 (0.85 to 30.0), and finasteride 1 mg oral: +12.0 (4.20 to 19.0); OTC agents ranked mid to low (e.g., rosemary topical SUCRA 53.6%; melatonin topical 55.4%; saw palmetto topical 14.1%).","limitations":"Efficacy was assessed only at 24 weeks; baseline disease duration was not accounted for. Many alternative‑agent trials enrolled relatively small numbers, and several studies showed risk‑of‑bias concerns. Network geometry limited some node‑splitting inconsistency assessments.","practice_takeaway":"At 6 months, dutasteride 0.5 mg daily ranks highest for increasing hair density, with finasteride (oral/topical) and topical minoxidil also outperforming control by clinically meaningful margins. OTC options like topical rosemary and melatonin show modest relative efficacy, while saw palmetto ranks low—use these data to set expectations when discussing nonprescription alternatives."}},{"doi":"10.1001/jamadermatol.2024.4593","pmid":"39565602","title":"Low-Dose Oral Minoxidil Initiation for Patients With Hair Loss","journal_title":"JAMA Dermatology","journal_issn":"2168-6068","published_at":"2024-11-20T00:00:00.000Z","url":"https://escholarship.org/uc/item/2pp1b5gc","source_score":91,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2024-11-24","doi":"10.1001/jamadermatol.2024.4593","days":"30","issn":"2168-6068","rank":"5","field":"Clinical Medicine","score":"91","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1001/jamadermatol.2024.4593","title":"Low-Dose Oral Minoxidil Initiation for Patients With Hair Loss: An International Modified Delphi Consensus Statement.","journal":"JAMA dermatology","methods":"","results":"","abstract":"$34","keywords":[],"pubmed_id":"39565602","conclusions":"","publication_date":"2024-11-20T00:00:00"},"crossref":{"DOI":"10.1001/jamadermatol.2024.4593","URL":"https://doi.org/10.1001/jamadermatol.2024.4593","ISSN":["2168-6068"],"link":[{"URL":"https://jamanetwork.com/journals/jamadermatology/articlepdf/2826573/jamadermatology_akiska_2024_cs_240009_1736781549.6292.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":"87","type":"journal-article","issue":"1","score":1,"title":["Low-Dose Oral Minoxidil Initiation for Patients With Hair Loss"],"author":[{"given":"Yagiz Matthew","family":"Akiska","sequence":"first","affiliation":[{"name":"George Washington University School of Medicine & Health Sciences, Washington, DC"}]},{"given":"Paradi","family":"Mirmirani","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The Permanente Medical Group, Vallejo, California"}]},{"given":"Ingrid","family":"Roseborough","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California, San Francisco"}]},{"given":"Erin","family":"Mathes","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California, San Francisco"}]},{"given":"Tina","family":"Bhutani","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California, San Francisco"}]},{"given":"Andrew","family":"Ambrosy","sequence":"additional","affiliation":[{"name":"Division of Research, Kaiser Permanente Northern California, San Francisco"},{"name":"Department of Cardiology, Kaiser Permanente San Francisco Medical Center, San Francisco, California"}]},{"given":"Crystal","family":"Aguh","sequence":"additional","affiliation":[{"name":"Johns Hopkins School of Medicine, Baltimore, Maryland"}]},{"given":"Wilma","family":"Bergfeld","sequence":"additional","affiliation":[{"name":"Departments of Dermatology and Pathology, Cleveland Clinic, Cleveland, Ohio"}]},{"given":"Valerie D.","family":"Callender","sequence":"additional","affiliation":[{"name":"Callender Dermatology, Washington, DC"},{"name":"Howard University College of Medicine, Washington, DC"},{"name":"Callendar Cosmetic Center, Baltimore, Maryland"}]},{"given":"Leslie","family":"Castelo-Soccio","sequence":"additional","affiliation":[{"name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Maryland"}]},{"given":"George","family":"Cotsarelis","sequence":"additional","affiliation":[{"name":"University of Pennsylvania, Philadelphia"}]},{"given":"Brittany Gareth","family":"Craiglow","sequence":"additional","affiliation":[{"name":"Yale School of Medicine, New Haven, Connecticut"}]},{"given":"Nisha S.","family":"Desai","sequence":"additional","affiliation":[{"name":"DermDX New England, Sonic Healthcare, Brighton, Massachusetts"}]},{"given":"Isabella","family":"Doche","sequence":"additional","affiliation":[{"name":"University of São Paulo Medical School, São Paulo, Brazil"}]},{"given":"Bruna","family":"Duque-Estrada","sequence":"additional","affiliation":[{"name":"Instituto de Dermatologia Prof Rubem David Azulay, Santa Casa de Misericórdia do Rio de Janeiro, Rio de Janeiro, Brazil"}]},{"given":"Dirk M.","family":"Elston","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The Medical University of South Carolina, Charleston, South Carolina"}]},{"given":"Carolyn","family":"Goh","sequence":"additional","affiliation":[{"name":"University of California, Los Angeles"}]},{"given":"Lynne J.","family":"Goldberg","sequence":"additional","affiliation":[{"name":"DermDX New England, Sonic Healthcare, Brighton, Massachusetts"},{"name":"Department of Dermatology, Boston University Chobanian and Avedisian School of Medicine, Boston, Massachusetts"}]},{"given":"Ramon","family":"Grimalt","sequence":"additional","affiliation":[{"name":"Universitat Internacional de Catalunya, Barcelona, Spain"}]},{"given":"Ali","family":"Jabbari","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Iowa, Iowa City, Iowa"},{"name":"Iowa City Veterans Affairs Medical Center, Iowa City, Iowa"}]},{"given":"Victoria","family":"Jolliffe","sequence":"additional","affiliation":[{"name":"Queen Mary University of London, London, United Kingdom"}]},{"given":"Brett A.","family":"King","sequence":"additional","affiliation":[{"name":"Yale School of Medicine, New Haven, Connecticut"}]},{"given":"Charlotte","family":"LaSenna","sequence":"additional","affiliation":[{"name":"University of Wisconsin–Madison"}]},{"given":"Yolanda","family":"Lenzy","sequence":"additional","affiliation":[{"name":"Lenzy Dermatology & Hair Loss Center, Chicopee, Massachusetts"},{"name":"Department of Dermatology, University of Connecticut, Farmington"}]},{"given":"Jenna C.","family":"Lester","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California, San Francisco"}]},{"given":"Nino","family":"Lortkipanidze","sequence":"additional","affiliation":[{"name":"David Tvildiani Medical University, Tbilisi, Georgia"}]},{"given":"Kristen I.","family":"Lo Sicco","sequence":"additional","affiliation":[{"name":"The Ronald O Perelman Department of Dermatology, New York University Langone Health, New York"}]},{"given":"Amy","family":"McMichael","sequence":"additional","affiliation":[{"name":"Wake Forest School of Medicine, Winston-Salem, North Carolina"}]},{"given":"Nekma","family":"Meah","sequence":"additional","affiliation":[{"name":"Mersey and West Lancashire NHS Trust, St Helens, United Kingdom"},{"name":"Faculty of Biology, Medicine and Health, Manchester University, Manchester, United Kingdom"}]},{"given":"Natasha","family":"Mesinkovska","sequence":"additional","affiliation":[{"name":"University of California, Irvine"}]},{"given":"Mariya","family":"Miteva","sequence":"additional","affiliation":[{"name":"Dr Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami, Miami, Florida"}]},{"given":"Arash","family":"Mostaghimi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Harvard Medical School, Brigham & Women’s Hospital, Boston, Massachusetts"}]},{"given":"Yuliya","family":"Ovcharenko","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Clinical Immunology, V.N. Karazin Kharkiv National University, Kharkiv, Ukraine"}]},{"given":"Melissa","family":"Piliang","sequence":"additional","affiliation":[{"name":"Cleveland Clinic, Cleveland, Ohio"}]},{"given":"Bianca Maria","family":"Piraccini","sequence":"additional","affiliation":[{"name":"Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy"},{"name":"Department of Experimental, Diagnostic and Specialty Medicine Alma Mater Studiorum, University of Bologna, Bologna, Italy"}]},{"given":"Adriana","family":"Rakowska","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Medical University of Warsaw, Warsaw, Poland"}]},{"given":"Kimberly S.","family":"Salkey","sequence":"additional","affiliation":[{"name":"Virginia Commonwealth University, Richmond, Virginia"}]},{"given":"Adriana","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Santa Monica Dermatology Group, Santa Monica, California"}]},{"given":"Jerry","family":"Shapiro","sequence":"additional","affiliation":[{"name":"New York University Grossman School of Medicine, New York"}]},{"given":"Cathryn","family":"Sibbald","sequence":"additional","affiliation":[{"name":"University of Toronto, The Hospital for Sick Children, Toronto, Ontario, Canada"}]},{"given":"Rodney","family":"Sinclair","sequence":"additional","affiliation":[{"name":"Sinclair Dermatology, Victoria, Australia"},{"name":"University of Melbourne, Melbourne, Victoria, Australia"}]},{"given":"Poonkiat","family":"Suchonwanit","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Medicine, Faculty of Medicine, Mahidol University, Ramathibodi Hospital, Bangkok, Thailand"}]},{"given":"Susan","family":"Taylor","sequence":"additional","affiliation":[{"name":"Perelman School of Medicine, University of Pennsylvania, Philadelphia"}]},{"given":"Antonella","family":"Tosti","sequence":"additional","affiliation":[{"name":"University of Miami, Miami, Florida"}]},{"given":"Sergio","family":"Vañó-Galván","sequence":"additional","affiliation":[{"name":"Dermatology Service, Ramon y Cajal Hospital and Grupo Pedro Jaen Clinic, IRYCIS, University of Alcala, Madrid, Spain"}]},{"given":"Dmitri Robert","family":"Wall","sequence":"additional","affiliation":[{"name":"Hair Restoration Blackrock, Dublin, Ireland"},{"name":"National and International Skin Registry Solutions (NISR), Belfield, Ireland"},{"name":"Charles Institute of Dermatology, University College Dublin, Dublin, Ireland"},{"name":"The Mater Misericordiae University Hospital, Dublin, Ireland"}]},{"given":"Jennifer M.","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California, San Francisco"},{"name":"Solano Dermatology Associates, Fairfield, California"}]}],"issued":{"date-parts":[[2025,1,1]]},"member":"10","prefix":"10.1001","source":"Crossref","volume":"161","created":{"date-time":"2024-11-20T16:00:33Z","timestamp":1732118433000,"date-parts":[[2024,11,20]]},"indexed":{"date-time":"2025-09-12T19:31:20Z","timestamp":1757705480748,"date-parts":[[2025,9,12]]},"subject":[],"abstract":"$35","language":"en","relation":{},"resource":{"primary":{"URL":"https://jamanetwork.com/journals/jamadermatology/fullarticle/2826573"}},"subtitle":["An International Modified Delphi Consensus Statement"],"deposited":{"date-time":"2025-01-15T16:01:09Z","timestamp":1736956869000,"date-parts":[[2025,1,15]]},"issn-type":[{"type":"print","value":"2168-6068"}],"published":{"date-parts":[[2025,1,1]]},"publisher":"American Medical Association (AMA)","reference":[{"DOI":null,"key":"dcs240009r1","year":"2017","issue":"6","author":"Phillips","volume":"96","first-page":"371","unstructured":null,"article-title":"Hair loss: common causes and treatment.","journal-title":"Am Fam Physician","doi-asserted-by":null},{"DOI":"10.1056/NEJM199909233411307","key":"dcs240009r2","year":"1999","issue":"13","author":"Price","volume":"341","first-page":"964","unstructured":null,"article-title":"Treatment of hair loss.","journal-title":"N Engl J Med","doi-asserted-by":"publisher"},{"DOI":"10.1001/jama.2020.19313","key":"dcs240009r3","year":"2021","issue":"9","author":"Mirmirani","volume":"325","first-page":"878","unstructured":null,"article-title":"Diagnosis and treatment of nonscarring hair loss in primary care in 2021.","journal-title":"JAMA","doi-asserted-by":"publisher"},{"DOI":"10.1111/dth.13950","key":"dcs240009r4","year":"2020","issue":"6","author":"Lemes","volume":"33","first-page":null,"unstructured":null,"article-title":"Topical and oral minoxidil for hair disorders in pediatric patients: what do we know so far?","journal-title":"Dermatol Ther","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2018.03.056","key":"dcs240009r5","year":"2019","issue":"5","author":"Freites-Martinez","volume":"80","first-page":"1199","unstructured":null,"article-title":"Hair disorders in cancer survivors.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1080/09546634.2021.1945527","key":"dcs240009r6","year":"2022","issue":"4","author":"Gupta","volume":"33","first-page":"1896","unstructured":null,"article-title":"Minoxidil: a comprehensive review.","journal-title":"J Dermatolog Treat","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2020.06.1009","key":"dcs240009r8","year":"2021","issue":"3","author":"Randolph","volume":"84","first-page":"737","unstructured":null,"article-title":"Oral minoxidil treatment for hair loss: a review of efficacy and safety.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2021.02.054","key":"dcs240009r9","year":"2021","issue":"6","author":"Vañó-Galván","volume":"84","first-page":"1644","unstructured":null,"article-title":"Safety of low-dose oral minoxidil for hair loss: a multicenter study of 1404 patients.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/dth.14106","key":"dcs240009r10","year":"2020","issue":"6","author":"Jimenez-Cauhe","volume":"33","first-page":null,"unstructured":null,"article-title":"Safety of low-dose oral minoxidil treatment for hair loss: a systematic review and pooled-analysis of individual patient data.","journal-title":"Dermatol Ther","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2022.05.026","key":"dcs240009r11","year":"2023","issue":"2","author":"Sanabria","volume":"88","first-page":"436","unstructured":null,"article-title":"Prospective cardiovascular evaluation with 24-hour Holter and 24-hour ambulatory blood pressure monitoring in men using 5-mg oral minoxidil for androgenetic alopecia.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2019.08.080","key":"dcs240009r12","year":"2021","issue":"3","author":"Wambier","volume":"85","first-page":"743","unstructured":null,"article-title":"Combination tofacitinib and oral minoxidil treatment for severe alopecia areata.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/ijd.16373","key":"dcs240009r13","year":"2023","issue":"2","author":"John","volume":"62","first-page":"257","unstructured":null,"article-title":"Systemic minoxidil for hair disorders in pediatric patients: a safety and tolerability review.","journal-title":"Int J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2022.04.030","key":"dcs240009r14","year":"2022","issue":"3","author":"de Nicolas-Ruanes","volume":"87","first-page":"700","unstructured":null,"article-title":"Low-dose oral minoxidil for treatment of androgenetic alopecia and telogen effluvium in a pediatric population: a descriptive study.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2023.12.073","key":"dcs240009r15","year":"2024","issue":"6","author":"Jackson","volume":"90","first-page":"1182","unstructured":null,"article-title":"Treatment for central centrifugal cicatricial alopecia—Delphi consensus recommendations.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":null,"key":"dcs240009r16","year":"2024","issue":"3","author":"Sanfilippo","volume":"23","first-page":"136","unstructured":null,"article-title":"Survey of dermatology practitioners’ opinions and prescribing habits of oral minoxidil for the treatment of androgenetic alopecia.","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":"10.1111/ijd.13838","key":"dcs240009r17","year":"2018","issue":"1","author":"Sinclair","volume":"57","first-page":"104","unstructured":null,"article-title":"Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone.","journal-title":"Int J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.12688/f1000research.11775.1","key":"dcs240009r18","year":"2017","issue":null,"author":"Perera","volume":"6","first-page":"1650","unstructured":null,"article-title":"Treatment of chronic telogen effluvium with oral minoxidil: a retrospective study.","journal-title":"F1000Res","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2023.02.024","key":"dcs240009r19","year":"2023","issue":"1","author":"Awad","volume":"89","first-page":"157","unstructured":null,"article-title":"Low-dose oral minoxidil improves hair density in traction alopecia.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2023.10.010","key":"dcs240009r20","year":"2024","issue":"2","author":"Ong","volume":"90","first-page":"425","unstructured":null,"article-title":"Low-dose oral minoxidil for androgenetic alopecia is not associated with clinically significant blood-pressure changes: a retrospective study.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2024.03.040","key":"dcs240009r21","year":"2024","issue":"2","author":"Moussa","volume":"91","first-page":"346","unstructured":null,"article-title":"Low-dose oral minoxidil improves hair length and global hair density in short anagen syndrome.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1093/ced/llad019","key":"dcs240009r22","year":"2023","issue":"5","author":"McFeely","volume":"48","first-page":"554","unstructured":null,"article-title":"Trichorrhexis nodosa improving with oral minoxidil: a case report.","journal-title":"Clin Exp Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jdcr.2022.09.035","key":"dcs240009r23","year":"2022","issue":null,"author":"Trüeb","volume":"30","first-page":"97","unstructured":null,"article-title":"Serious complication of low-dose oral minoxidil for hair loss.","journal-title":"JAAD Case Rep","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jdcr.2022.07.044","key":"dcs240009r24","year":"2022","issue":null,"author":"Dlova","volume":"28","first-page":"94","unstructured":null,"article-title":"Pericardial, pleural effusion and anasarca: a rare complication of low-dose oral minoxidil for hair loss.","journal-title":"JAAD Case Rep","doi-asserted-by":"publisher"},{"DOI":"10.1046/j.1365-2648.2003.02537.x","key":"dcs240009r25","year":"2003","issue":"4","author":"Powell","volume":"41","first-page":"376","unstructured":null,"article-title":"The Delphi technique: myths and realities.","journal-title":"J Adv Nurs","doi-asserted-by":"publisher"},{"DOI":"10.1136/bmjqs-2015-004411","key":"dcs240009r26","year":"2016","issue":"12","author":"Ogrinc","volume":"25","first-page":"986","unstructured":null,"article-title":"SQUIRE 2.0 (Standards for QUality Improvement Reporting Excellence): revised publication guidelines from a detailed consensus process.","journal-title":"BMJ Qual Saf","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jbi.2019.103208","key":"dcs240009r27","year":"2019","issue":null,"author":"Harris","volume":"95","first-page":null,"unstructured":null,"article-title":"The REDCap consortium: building an international community of software platform partners.","journal-title":"J Biomed Inform","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2020.03.004","key":"dcs240009r28","year":"2020","issue":"1","author":"Meah","volume":"83","first-page":"123","unstructured":null,"article-title":"The Alopecia Areata Consensus of Experts (ACE) study: results of an international expert opinion on treatments for alopecia areata.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2020.09.028","key":"dcs240009r29","year":"2021","issue":"6","author":"Meah","volume":"84","first-page":"1594","unstructured":null,"article-title":"The Alopecia Areata Consensus of Experts (ACE) study part II: results of an international expert opinion on diagnosis and laboratory evaluation for alopecia areata.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2020.5839","key":"dcs240009r30","year":"2021","issue":"4","author":"Wall","volume":"157","first-page":"1","unstructured":null,"article-title":"A global eDelphi exercise to identify core domains and domain items for the development of a Global Registry of Alopecia Areata Disease Severity and Treatment Safety (GRASS).","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2023.5869","key":"dcs240009r31","year":"2024","issue":"3","author":"Moussa","volume":"160","first-page":"341","unstructured":null,"article-title":"The Alopecia Areata Severity and Morbidity Index (ASAMI) study: results from a global expert consensus exercise on determinants of alopecia areata severity.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jid.2017.05.014","key":"dcs240009r32","year":"2017","issue":"9","author":"Spuls","volume":"137","first-page":"2014","unstructured":null,"article-title":"The International TREatment of ATopic Eczema (TREAT) Registry Taskforce: an initiative to harmonize data collection across national atopic eczema photo- and systemic therapy registries.","journal-title":"J Invest Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1186/s13063-016-1765-7","key":"dcs240009r33","year":"2017","issue":"1","author":"Gerbens","volume":"18","first-page":"87","unstructured":null,"article-title":"TREatment of ATopic eczema (TREAT) Registry Taskforce: protocol for an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema registries.","journal-title":"Trials","doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.16714","key":"dcs240009r34","year":"2019","issue":"4","author":"Gerbens","volume":"180","first-page":"790","unstructured":null,"article-title":"TREatment of ATopic eczema (TREAT) Registry Taskforce: an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema photo- and systemic therapy registries.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2020.04.027","key":"dcs240009r35","year":"2022","issue":"2","author":"Therianou","volume":"86","first-page":"429","unstructured":null,"article-title":"How safe is prescribing oral minoxidil in patients allergic to topical minoxidil?","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":null,"key":"dcs240009r7","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"US Food and Drug Administration. Loniten (minoxidil). Pfizer Inc. January 2015. Accessed October 15, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/018154s026lbl.pdf","article-title":null,"journal-title":null,"doi-asserted-by":null}],"short-title":[],"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,1]]}},"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["JAMA Dermatology"],"published-print":{"date-parts":[[2025,1,1]]},"reference-count":35,"published-online":null,"references-count":35,"short-container-title":["JAMA Dermatol"],"is-referenced-by-count":5},"unpaywall":{"doi":"10.1001/jamadermatol.2024.4593","is_oa":true,"title":"Low-Dose Oral Minoxidil Initiation for Patients With Hair Loss","updated":"2025-09-06T02:51:56+00:00","published_date":"2024-11-20","best_oa_location":{"url":"https://escholarship.org/uc/item/2pp1b5gc","pmh_id":"oai:escholarship.org:ark:/13030/qt2pp1b5gc","url_for_pdf":null,"url_for_landing_page":"https://escholarship.org/uc/item/2pp1b5gc"}}},"created_at":"2025-09-20T03:51:21.142Z","updated_at":"2025-09-20T06:15:05.187Z","tags":[{"paper_doi":"10.1001/jamadermatol.2024.4593","tag_type":"age_group","value":"adolescent","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4593","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4593","tag_type":"brand","value":"Loniten","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4593","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4593","tag_type":"condition","value":"Alopecia Areata","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4593","tag_type":"condition","value":"Androgenetic Alopecia","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4593","tag_type":"condition","value":"Central Centrifugal Cicatricial Alopecia","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4593","tag_type":"condition","value":"Chemotherapy-Induced Alopecia","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4593","tag_type":"condition","value":"Endocrine Therapy-Induced Alopecia","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4593","tag_type":"condition","value":"Frontal Fibrosing Alopecia","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4593","tag_type":"condition","value":"Lichen Planopilaris","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4593","tag_type":"condition","value":"Telogen Effluvium","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4593","tag_type":"generic","value":"minoxidil","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4593","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4593","tag_type":"level_of_evidence","value":"7","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4593","tag_type":"modality","value":"Vasodilator","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4593","tag_type":"sample_size","value":"n=43","value_numeric":43},{"paper_doi":"10.1001/jamadermatol.2024.4593","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4593","tag_type":"study_design","value":"Delphi Consensus","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4593","tag_type":"warning","value":"Design classification reflects an expert Delphi consensus, not patient-level comparative evidence.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4593","tag_type":"warning","value":"Pediatric dosing (<12 years) and titration protocols did not reach consensus.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4593","tag_type":"warning","value":"Percentages denote panel agreement, not treatment effect sizes or event rates.","value_numeric":null}],"summaries":{"what_studied":"An international modified Delphi process among 43 hair-loss dermatologists from 12 countries (March 21, 2023–January 22, 2024) to generate consensus recommendations for initiating low-dose oral minoxidil for hair loss, with consensus defined as ≥70% agreement.","key_result":"Across 4 rounds, 76 items reached consensus, including: consider LDOM for adults and adolescents (93.0% and 86.0%); direct benefit in AGA and age‑related thinning (97.7% each); typical starting doses—female adults 1.25 mg/day (74.4%), male adults 2.5 mg/day (74.4%)—with ranges up to 5 mg/day; avoid in pregnancy/breastfeeding (95.5%); baseline labs and ECG not routine absent precautions (90.7% and 93.0%); counsel that vasodilation effects may appear in 3–7 days, fluid retention in 4–6 weeks, and earliest efficacy at 3 months.","limitations":"Findings reflect expert opinion rather than patient outcomes; pediatric experts were underrepresented and no consensus was reached for children <12 years or for titration protocols. Guidance for patients with true minoxidil allergy remains unresolved.","practice_takeaway":"When topical minoxidil is ineffective, impractical, or irritant, experts support considering LDOM in adults and adolescents, typically starting at 1.25 mg/day (female) or 2.5 mg/day (male), individualized by risk and goals, and avoiding use in pregnancy or breastfeeding. Skip routine baseline labs/ECG unless precautions exist; monitor blood pressure and counsel patients to watch for tachycardia/dizziness within 3–7 days, edema/weight gain by 4–6 weeks, and expect earliest hair response by 3 months."}},{"doi":"10.1001/jamadermatol.2024.0284","pmid":"38598226","title":"Oral Minoxidil vs Topical Minoxidil for Male Androgenetic Alopecia","journal_title":"JAMA Dermatology","journal_issn":"2168-6068","published_at":"2024-04-10T00:00:00.000Z","url":"https://doi.org/10.1001/jamadermatol.2024.0284","source_score":77,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2024-04-24","doi":"10.1001/jamadermatol.2024.0284","days":"30","issn":"2168-6068","rank":"5","field":"Clinical Medicine","score":"77","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1001/jamadermatol.2024.0284","title":"Oral Minoxidil vs Topical Minoxidil for Male Androgenetic Alopecia: A Randomized Clinical Trial.","journal":"JAMA dermatology","methods":"","results":"$36","abstract":"$37","keywords":[],"pubmed_id":"38598226","conclusions":"","publication_date":"2024-04-10T00:00:00"},"crossref":{"DOI":"10.1001/jamadermatol.2024.0284","URL":"https://doi.org/10.1001/jamadermatol.2024.0284","ISSN":["2168-6068"],"link":[{"URL":"https://jamanetwork.com/journals/jamadermatology/articlepdf/2817326/jamadermatology_penha_2024_oi_240007_1717692707.53019.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":"600","type":"journal-article","issue":"6","score":1,"title":["Oral Minoxidil vs Topical Minoxidil for Male Androgenetic Alopecia"],"author":[{"given":"Mariana Alvares","family":"Penha","sequence":"first","affiliation":[{"name":"Department of Dermatology, Faculty of Medicine of Botucatu, São Paulo State University (UNESP), Botucatu, Brazil"}]},{"given":"Hélio Amante","family":"Miot","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Faculty of Medicine of Botucatu, São Paulo State University (UNESP), Botucatu, Brazil"}]},{"given":"Michal","family":"Kasprzak","sequence":"additional","affiliation":[{"name":"TrichoLAB GmbH, Warsaw, Poland"}]},{"given":"Paulo","family":"Müller Ramos","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Faculty of Medicine of Botucatu, São Paulo State University (UNESP), Botucatu, Brazil"}]}],"issued":{"date-parts":[[2024,6,1]]},"member":"10","prefix":"10.1001","source":"Crossref","volume":"160","created":{"date-time":"2024-04-10T15:01:17Z","timestamp":1712761277000,"date-parts":[[2024,4,10]]},"indexed":{"date-time":"2025-09-19T08:26:13Z","timestamp":1758270373530,"date-parts":[[2025,9,19]]},"subject":[],"abstract":"$38","language":"en","relation":{},"resource":{"primary":{"URL":"https://jamanetwork.com/journals/jamadermatology/fullarticle/2817326"}},"subtitle":["A Randomized Clinical Trial"],"deposited":{"date-time":"2024-06-19T15:01:08Z","timestamp":1718809268000,"date-parts":[[2024,6,19]]},"issn-type":[{"type":"print","value":"2168-6068"}],"published":{"date-parts":[[2024,6,1]]},"publisher":"American Medical Association (AMA)","reference":[{"DOI":"10.1111/j.1087-0024.2005.10102.x","key":"doi240007r1","year":"2005","issue":"3","author":"Gan","volume":"10","first-page":"184","unstructured":null,"article-title":"Prevalence of male and female pattern hair loss in Maryborough.","journal-title":"J Investig Dermatol Symp Proc","doi-asserted-by":"publisher"},{"DOI":"10.1590/abd1806-4841.20153370","key":"doi240007r2","year":"2015","issue":"4","author":"Ramos","volume":"90","first-page":"529","unstructured":null,"article-title":"Female pattern hair loss: a clinical and pathophysiological review.","journal-title":"An Bras Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1046/j.1365-2133.1999.03030.x","key":"doi240007r3","year":"1999","issue":"3","author":"Cash","volume":"141","first-page":"398","unstructured":null,"article-title":"The psychosocial consequences of androgenetic alopecia: a review of the research literature.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2021.5743","key":"doi240007r4","year":"2022","issue":"3","author":"Gupta","volume":"158","first-page":"266","unstructured":null,"article-title":"Relative efficacy of minoxidil and the 5-a reductase inhibitors in androgenetic alopecia treatment of male patients: a network meta-analysis.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.abd.2020.02.001","key":"doi240007r5","year":"2020","issue":"3","author":"Pereira","volume":"95","first-page":"271","unstructured":null,"article-title":"Post-finasteride syndrome.","journal-title":"An Bras Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1080/09546630701383727","key":"doi240007r6","year":"2007","issue":"5","author":"Mapar","volume":"18","first-page":"268","unstructured":null,"article-title":"Is topical minoxidil solution effective on androgenetic alopecia in routine daily practice?","journal-title":"J Dermatolog Treat","doi-asserted-by":"publisher"},{"DOI":"10.33589/33.3.93","key":"doi240007r7","year":"2023","issue":null,"author":"Muller Ramos","volume":"33","first-page":"93","unstructured":null,"article-title":"Oral minoxidil for hair loss: update and perspectives.","journal-title":"Hair Transplant Forum Int","doi-asserted-by":"publisher"},{"DOI":"10.4103/ijt.ijt_46_17","key":"doi240007r8","year":"2017","issue":"3","author":"Wirya","volume":"9","first-page":"95","unstructured":null,"article-title":"Classification of male-pattern hair loss.","journal-title":"Int J Trichology","doi-asserted-by":"publisher"},{"DOI":"10.1016/0197-2456(94)90015-9","key":"doi240007r9","year":"1994","issue":"2","author":"Overall","volume":"15","first-page":"100","unstructured":null,"article-title":"Estimating sample sizes for repeated measurement designs.","journal-title":"Control Clin Trials","doi-asserted-by":"publisher"},{"DOI":"10.1159/000497193","key":"doi240007r10","year":"2019","issue":"4","author":"Kasprzak","volume":"5","first-page":"216","unstructured":null,"article-title":"Follicular map: a novel approach to quantitative trichoscopy.","journal-title":"Skin Appendage Disord","doi-asserted-by":"publisher"},{"DOI":"10.1159/000524345","key":"doi240007r11","year":"2022","issue":"5","author":"Bokhari","volume":"8","first-page":"382","unstructured":null,"article-title":"Efficiency of hair detection in hair-to-hair matched trichoscopy.","journal-title":"Skin Appendage Disord","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi240007r12","year":"2003","issue":"6","author":"Narins","volume":"29","first-page":"588","unstructured":null,"article-title":"A randomized, double-blind, multicenter comparison of the efficacy and tolerability of Restylane versus Zyplast for the correction of nasolabial folds.","journal-title":"Dermatol Surg","doi-asserted-by":null},{"DOI":"10.1590/1677-5449.190004","key":"doi240007r13","year":"2019","issue":null,"author":"Miot","volume":"18","first-page":null,"unstructured":null,"article-title":"Anomalous values and missing data in clinical and experimental studies.","journal-title":"J Vasc Bras","doi-asserted-by":"publisher"},{"DOI":"10.1590/1677-5449.041117","key":"doi240007r14","year":"2017","issue":null,"author":"Miot","volume":null,"first-page":"88","unstructured":null,"article-title":"Assessing normality of data in clinical and experimental trials.","journal-title":"J Vasc Bras","doi-asserted-by":"publisher"},{"DOI":"10.1038/nprot.2016.048","key":"doi240007r15","year":"2016","issue":"6","author":"Duricki","volume":"11","first-page":"1112","unstructured":null,"article-title":"Analysis of longitudinal data from animals with missing values using SPSS.","journal-title":"Nat Protoc","doi-asserted-by":"publisher"},{"DOI":"10.1590/1677-5449.210038","key":"doi240007r16","year":"2021","issue":null,"author":"Miola","volume":"20","first-page":null,"unstructured":null,"article-title":"P value and effect-size in clinical and experimental studies.","journal-title":"J Vasc Bras","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJM198012183032516","key":"doi240007r17","year":"1980","issue":"25","author":"Zappacosta","volume":"303","first-page":"1480","unstructured":null,"article-title":"Reversal of baldness in patient receiving minoxidil for hypertension.","journal-title":"N Engl J Med","doi-asserted-by":"publisher"},{"DOI":"10.1007/s13555-020-00448-x","key":"doi240007r18","year":"2020","issue":"6","author":"Panchaprateep","volume":"10","first-page":"1345","unstructured":null,"article-title":"Efficacy and safety of oral minoxidil 5 mg once daily in the treatment of male patients with androgenetic alopecia: an open-label and global photographic assessment.","journal-title":"Dermatol Ther (Heidelb)","doi-asserted-by":"publisher"},{"DOI":"10.1111/ijd.v61.5","key":"doi240007r19","year":"2022","issue":"5","author":"Müller-Ramos","volume":"61","first-page":"e162","unstructured":null,"article-title":"Post—COVID-19 hair loss: prevalence and associated factors among 5,891 patients.","journal-title":"Int J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2019.08.060","key":"doi240007r20","year":"2020","issue":"1","author":"Ramos","volume":"82","first-page":"252","unstructured":null,"article-title":"Minoxidil 1 mg oral versus minoxidil 5% topical solution for the treatment of female-pattern hair loss: a randomized clinical trial.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2022.05.026","key":"doi240007r21","year":"2023","issue":"2","author":"Sanabria","volume":"88","first-page":"436","unstructured":null,"article-title":"Prospective cardiovascular evaluation with 24-hour Holter and 24-hour ambulatory blood pressure monitoring in men using 5-mg oral minoxidil for androgenetic alopecia.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2020.11.035","key":"doi240007r22","year":"2021","issue":"4","author":"Sanabria","volume":"84","first-page":"1175","unstructured":null,"article-title":"Adverse effects of low-dose oral minoxidil for androgenetic alopecia in 435 patients.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2021.02.054","key":"doi240007r23","year":"2021","issue":"6","author":"Vañó-Galván","volume":"84","first-page":"1644","unstructured":null,"article-title":"Safety of low-dose oral minoxidil for hair loss: a multicenter study of 1404 patients.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2010.09.724","key":"doi240007r24","year":"2011","issue":"6","author":"Blume-Peytavi","volume":"65","first-page":"1126","unstructured":null,"article-title":"A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"}],"short-title":[],"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6,1]]}},"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["JAMA Dermatology"],"published-print":{"date-parts":[[2024,6,1]]},"reference-count":24,"published-online":null,"references-count":24,"short-container-title":["JAMA Dermatol"],"is-referenced-by-count":27},"unpaywall":{"doi":"10.1001/jamadermatol.2024.0284","is_oa":false,"title":"Oral Minoxidil vs Topical Minoxidil for Male Androgenetic Alopecia","updated":"2025-06-20T04:27:11+00:00","published_date":"2024-04-10","best_oa_location":null}},"created_at":"2025-09-20T07:52:19.108Z","updated_at":"2025-09-20T08:45:45.348Z","tags":[{"paper_doi":"10.1001/jamadermatol.2024.0284","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.0284","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.0284","tag_type":"condition","value":"Androgenetic Alopecia","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.0284","tag_type":"generic","value":"minoxidil","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.0284","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.0284","tag_type":"modality","value":"Vasodilator","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.0284","tag_type":"sample_size","value":"n=90","value_numeric":90},{"paper_doi":"10.1001/jamadermatol.2024.0284","tag_type":"sex","value":"male","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.0284","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.0284","tag_type":"warning","value":"Enrollment (n=90) vs completer counts (33 vs 35) and safety denominators (n=45 oral) are not fully reconciled in the abstract.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.0284","tag_type":"warning","value":"The photographic analysis favored oral therapy at the vertex, but the abstract does not describe the photographic scoring method or its clinical significance.","value_numeric":null}],"summaries":{"what_studied":"A double-blind, placebo-controlled randomized trial at a single Brazilian clinic compared oral minoxidil 5 mg once daily with topical minoxidil 5% twice daily for 24 weeks in men aged 18–55 years with androgenetic alopecia (Norwood-Hamilton 3V–5V).","key_result":"Oral minoxidil did not show superiority over topical minoxidil for the primary outcome of terminal hair density at 24 weeks on the frontal (between-group mean change 3.1 hairs/cm²; 95% CI, -18.2 to 21.5; P=.27) or vertex scalp (23.4 hairs/cm²; 95% CI, -0.3 to 43.0; P=.09). Photographic analysis favored oral minoxidil on the vertex (24%; 95% CI, 0 to 48; P=.04) but not the frontal scalp (12%; 95% CI, -12 to 36; P=.24). Hypertrichosis (22/45 [49%]) and headache (6/45 [14%]) were the most common adverse effects with oral therapy.","limitations":"Single-center study with a 24-week duration and attrition (68 of 90 completed). The abstract reports completer counts per arm, while safety data suggest 45 per oral arm, leaving randomization and analysis populations unclear.","practice_takeaway":"For male AGA over 24 weeks, oral minoxidil 5 mg daily did not outperform topical 5% twice daily on hair density; a vertex photographic edge was small and method-limited. Expect frequent hypertrichosis with oral therapy; weigh tolerability when choosing route."}}],"initialOffset":12,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"condition","value":"Androgenetic Alopecia"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Conditions","href":"/hub/tag/condition"},{"name":"Androgenetic Alopecia"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"condition","hub_tag_value":"Androgenetic Alopecia"}}}]]

Papers